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ABSTRACT
Examining Unused Pharmaceuticals
in the Environment

by

Ilene Sue Ruhoy

Dr. David M. Hassenzahl, Committee Chair
Chair, Department o f Environmental Studies
University o f Nevada, Las Vegas

Unused pharmaceuticals take an unhealthy toll on both the environment and human
health. In the US alone, an estimated $1 billion o f prescription drugs are thrown away
eaeh year. Increasing availability, marketing, and purchasing o f both prescription and
over-the-counter medications, coupled with the tendeney o f patients to discontinue use of
and to stockpile drugs at home, is a unique problem that has garnered inereasing attention
among seientists, policymakers, and the media in the last ten years.
These aceumulated household drugs beeome unused pharmaeeutical waste. This
w a ste m ust b e disearded and d isp osed o f b y the consum er. H istorically, con su m ers have

been instrueted by health care professionals to dispose o f unwanted medieations into the
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sewage system. Inserts in some pharmaeeutieal paekaging have also instrueted eonsumer
to flush expired and unused medications down the toilet. This method has historically
also applied to pharmaceuticals stored in locations other than the consumer household.
In the past decade studies have consistently identified amounts o f pharmaceutical
residues in water systems throughout the country. However, it has yet to be determined if
the source of these substances found in the waterways is from excretion or disposal.
While it is most likely a combination o f both, it has been difficult to assess to what extent
disposal takes place. Namely, there has been no source o f data that would convey how
often disposal takes place, what are the more common pharmaceutical compounds
disposed, and in what quantities these compounds are flushed into our sewage systems.
This dissertation deseribes a new methodology - eompiling inventory data from
coroner offices - which can provide a source o f data detailing exactly how much o f a
specific pharmaceutical ingredient has been disposed in a particular geographic area and
the frequency with which that compound is found in the disposal inventories. Further,
this work assesses the many, varied, and often overlooked sites o f accumulation o f
unused medications, the approximate relative contributions generated at each site, and
common reasons why they accumulate in their respective locations. Finally, this work
assesses the risk associated with inappropriate transfers o f pharmaceuticals, and potential
means for mitigating the risks.
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CHAPTER 1

INTRODUCTION
The occurrence o f traee levels of pharmaeeutieals in the environment ean be the result
o f intended use, via excretion or bathing, or disposal o f the drug via either the toilet or the
trash. Every pharmaeeutieal ingredient has its own pharmaeokinetie profile that will
dietate how mueh o f the parent drug, or one its metabolites, will be exereted by both the
kidney and the bowel. Bathing ean result in transfer o f some compounds to the
environment from use o f topically applied medieations.
Disposal represents a direct introduction o f the parent eompound into the
environment. This transfer into the environment oeeurs following the non-use o f the drug
as it was originally intended, either by preseription or by its storage in a partieular site.
For example, expired drugs from first-aid kits are routinely flushed and replenished.
Pharmaeeutieals go unused for a variety o f reasons. Patients may voluntarily
diseontinue therapy due to expiration, adverse efleets, side effeets, ehange in medieation
regimen, or poor pereeption of the extent o f illness. Studies report 15% o f all hospital
admissions in 2003 were due to poor eomplianee or eomplete eessation o f therapy (Gold
and MeClung, 2006). Poor adherenee has been estimated to eost approximately $177
billion annually in health eare eosts (NCPIE, 2007). A reeent survey found that 49% of
respondents admitted to forgetting to take their preseribed medieation (NCPA, 2006).

This can lead to an inordinate amount o f stockpiling o f medications in the home - all of
which ultimately have to be disposed of.
If the drugs were not to be disposed and instead are allowed to aeeumulate in their
respeetive loeations, the eoneem is the eonsequent availability for inappropriate usage of
the drugs - either intentionally or unintentionally. There is often a false sense o f safety
with pharmaeeutieals. They are ubiquitous, sold in pharmacies, and prescribed by trusted
physieians. Drugs are often left unseeured. The Ameriean Assoeiation o f Poison Control
Centers reports that there were approximately 1.5 million pharmaeeutieal exposures
reported to poison eontrol centers in 2004 (Watson, 2005). An exposure, as defined by
the AAPCC, refers to an inquiry made to a eertified poison eenter regarding the
unintended use or eontaet with a preseribed medieation. Almost 2,500 o f these exposures
resulted in death. The National Center on Addietion and Substanee AbUse reported a
212% inerease in the use o f eontrolled drugs by teenagers between 1992 and 2003
(CASA 2003).
The disposal pathway for unused medieations is governed by preseription praetiees
and personal behavior. There are two main routes for pharmaeeutieals to enter the
environment. The first is through normal usage o f medieines. After administration, a
quantity o f the drug, or its metabolites, is exereted from the body. The pharmaeokinetie
profile o f the drug, the dosage consumed, the physiology o f the individual, and the
efficieney of the wastewater treatment governs release and eventual exposure via this
I

pathway. When a person eonsumes a medieation, depending upon the ehemieal strueture,
metabolism, and bioehemical interaetion o f the drug, as well as some gerietie variability
in physiology, the drug may be either transformed (yielding one or more metabolites)

which are then released from the body, or excreted unaltered with its chemical structure

intact.
The second route by which pharmaceuticals can enter the environment, and the focus
o f this research, is the disposal o f out-of-date, unused, or unwanted medicines, which
may occur via the sink/toilet or in household garbage that is then taken to landfill sites.
Entry into the environment by this route depends on the habits o f the patient and the
efficiency o f prescription practices leading to fewer unfinished prescriptions.
Kuspis and Krenzelok (1996) reported that only 1.4% o f Americans surveyed
returned unused medication to the pharmacy, whereas 54% threw them in the trash, and
35.4% disposed o f them in the sink/toilet. For most people, household garbage is the
most straightforward and least time-consuming method o f disposal. Even if the return of
all pharmaceuticals to a pharmacist or a physician were legal, there is no monetary
incentive to return medicines to the pharmacy and it requires more effort than simply
discarding them. There would have to be another motivating factor employed to entice
the public to participate in a return system o f their unused medication.
The question o f how to dispose o f unwanted and unused pharmaceuticals is proving
to be a daunting task. Historically, consumers have been directed by healthcare
professionals (i.e., doctors and pharmacists) and poison control centers to flush the
medications down the toilet, then pour them down the sink, or throw them into household
trash. US Drug Enforcement Administration (DEA) regulations strictly control the
transfer o f drugs that are controlled substances under the Controlled Substances Act
(CSA) (US DOJ, 1970). The CSA was enacted into law by the Congress o f the United
States as Title II of the Comprehensive Drug Abuse Prevention and Control Act o f 1970.

This law prohibits the transference o f any eontrolled substanee from the prescribed

individual to any entity other than law enforeement. The eonsumer is considered the end
user and eannot transfer the eontrolled medieation to anyone, ineluding a physieian or a
pharmaeist. This is one o f the reasons that most pharmaeies will not accept returns from
patients.
Abuse of prescription analgesics in 2007 ranks second— only behind marijuana— as
the Nation's most prevalent illegal drug problem (ONDCP, 2008). In an effort to eombat
the rising rates o f preseription drug abuse, the White House Offiee o f National Drug
Control Poliey (ONDCP, 2007) has established the first Federal guidelines for proper
disposal o f unused drugs. These guidelines, released in February 2007, direet consumers
to adulterate unwanted medications by mixing with an unpalatable substanee and then
disposing into the household trash. Yet the guidelines also inelude a list of medications
with either a perceived or known risk o f diversion and toxieity. In order to avoid potential
publie health eonsequenees, consumers are instrueted to flush these medieations to ensure
they are not available to those who are inelined to sort through public trash or to those
who might aeeidentally ingest them, sueh as toddlers or pets.

Environmental and Human Health Impaets
The unexamined disposal o f unwanted medieations has led to eoneem with regard to
the health of the environment beginning in the 1970’s when seientists began to reveal the
ability o f pharmaceuticals to enter the environment. Garrison et al. (1976) first reported
elofibrie aeid (the aetive metabolite from the lipid regulators elofibrate, etofibrate, and
theofibrate) in raw sewage and aetivated sludge effluent. Hignite and A zam off (1977)

reported the detection o f salicylic acid and other drug metabolites in the influent and

effluent o f a sewage treatment plant in Missouri. A landmark monitoring study published
in 2002 by the United States Geological Survey (USGS, 2002) found that 80% of 139
streams sampled across 30 states detected (albeit at low concentrations) chemicals
commonly found in prescription drugs.
In waterways from the Potomac to the Brazos River in Texas, researchers have found
fish exposed to trace levels of estrogens and antidepressants, and many show evidence of
neurological or physiological changes (Folmar et ah, 16; Ying, 2008). Several studies
have demonstrated detrimental effects on fish species such as alterations in sex ratios,
other endocrine disturbances, and abnormal social behaviors (Cleuvers, 2004; Fent et ah,

y
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Advances in analytical chemistry enable us to irrefutably decipher residues of
pharmaceuticals in the environment. Detection of chemical compounds at concentrations
o f parts per billion and parts per trillion are now possible (Hirsch et al. 1999). A recently
published study in the Netherlands concluded, based on calculated hazard quotients, the
effects o f fluoxetine, ibuprofen, and carbamazepine, three very commonly prescribed
drugs, place the “environment at risk” (De Lange et al., 2006).
The assessment o f detrimental and deleterious effects on the environment includes
not only an understanding o f the chemical and biological interfaces, but also o f the
sources from which the chemicals come. Accumulation o f pharmaceuticals occurs at
many different points in our communities. The sources of pharmaceutical accumulation
are the end sites o f the drugs - the location they may be found prior to their disposal or
perpetual storage. Regardless of the method o f disposal, commonly prescribed

medications leave the manufacturer for a fate o f either consumption or non-consumption.
Non-consumed drugs end up in many sites, including schools and child care facilities,
hospitals, nursing homes, hospice eare centers, doctor and dentist offices, public use first
aid kits, veterinarian offices, farms, military bases, and prisons (Ruhoy and Daughton,

2008).
That pharmaceutical chemicals found in the environment pose a substantial threat to
human life is a natural assumption. Data on long-term impacts on human health is limited
and varied, but some evidence does seem to point to potential effects. Epidemiological
research designed to explore causality o f illness has produced increasing evidence that
exposure to toxic agents contributes to the escalating burden o f human chronic affliction
(Hu, 2003; CDC, 2005). Most pharmaceuticals are designed to target specific molecular
structures on human cellular receptors. Many receptors are evolutionarily conserved.
Their structure and design are ubiquitous among humans as well as across many different
species.
A definitive understanding o f the relationship between the disposal o f
pharmaceuticals and environmental impacts still eludes us. The chasms o f knowledge
with respect to amounts, sources, and interactions stalls the implementation o f policy to
guide the disposal o f drugs that are not used as originally intended. A common
controversy is the relative contributions o f disposal and human excretion to
pharmaceutical residues found in the environment. It is not currently known what
I
portions o f the pharmaceutical ingredients found in the environment originate from
human disposal.

On a basic level, the extent o f disposal o f unused medications is poorly documented.
An evaluation o f human disposal would include rates o f prescription and rates and
degrees o f non-compliance o f the most commonly prescribed medications. Noncompliance, referring either to the complete cessation of medication consumption or an
alteration to the original treatment plan as directed by a health care practitioner, rates are
difficult to assess, however, and the literature often reports varying rates depending upon
the disease treated and the treatment used (see Demyttenaere et ah, 2008; Home, 2006;
Rains et ah, 2006). Even so, an assessment o f medication disposal would have to assume
a certain percentage of consumers dispose of the dmgs while others simply accumulate
unused.
While the precise chemical structure o f the drugs entering the environment is well
known for those instances o f disposal, we would still need to further our understanding of
its effects on the environment including its retention in our waterways. Currently, our
wastewater treatment works are not equipped to remove all pharmaceuticals, or their
metabolites. Studies have shown that many pharmaceuticals are not fully removed by
sewage treatment systems (Petrovic and Barcelo, 2007). In addition, a comprehensive
environmental risk assessment would have to include a spectrum o f alternative doseresponse relationships, such as the potential synergistic and/or additive effects among the
chemicals.
The literature on pharmaceuticals in the environment has exponentially increased
during the past decade. The research has mainly focused on the detection and
quantification o f pharmaceutical compounds found in natural resources as well as some
theoretical examination o f the correlation between these compounds and the

physiological alterations and aberrations reeently seen in aquatie life. There is seant
literature on the reasons and amounts o f drugs that are disposed and whether this disposal
is at all responsible for the concentrations reported in the environment.
This dissertation analyzes the problem o f where, how much, and why
pharmaceuticals accumulate where they go unused. This issue has garnered attention by
many, often competing, interests and factions. One objective is to design a complete
assessment o f unused pharmaceutical chemicals and the extent and result o f their
disposal. This contributes to the growing body o f knowledge as we begin to understand
the extent to which drugs accumulate in our society and then in our natural environment.
An ultimate goal would be to foster practices that would lead to reducing the amount of
leftover pharmaceuticals, primarily by improving prescription and dispensing behaviors
as well as patient compliance. An understanding o f the factors governing usage and noncompliance would help to drastically reduce the amount o f leftover drugs. To improve
patient compliance in the US would not only decrease the quantity o f medications to be
disposed of, since they would be consumed instead, but would also increase the
physician’s ability to treat and thereby improve patient outcomes. The continuing surge
o f prescription rates likely leads to both an increase in use o f the drugs and to an increase
in non-use.
The pharmaceutical industry continues to develop new molecular entities and,
perhaps more importantly, introduces thousands o f new formulations and patents on
existing chemical entities each year, using isomers o f chemical structures already used in
clinical medicine. The approval process for new drugs and the post-marketing safety
surveillance is fraught with flaws and inadequacies (Michaels, 2008). While these

medications certainly save and improve human lives, the irresponsible and unregulated

prescribing o f these compounds results in waste. If we are to create a sustainable
healthcare system, the environment should be protected from increasing advancements in
and continual changes in pharmaceutical chemicals that are not used as intended and
subsequently enter the ecosystem, which has not necessarily evolved to withstand the
consistent and chronic introduction o f toxic foreign compounds. Our environment is
resilient but can we expect it to continue to withstand and endure further burden? This
will require all those involved in the development, manufacturing, distributing,
prescribing, regulating, and utilizing these pharmaceutical chemicals to collaborate to
devise a plan to better manage the perception, reception, acceptance, and use o f drugs in
this country.
This dissertation estimates amounts o f releases (Chapter two), the range o f
accumulation locations in society (Chapter three) and mitigation strategies including
pollution prevention (Chapter three) and four-stage risk management (Chapter four). It
concludes in Chapter five with a discussion on the impact o f this research and
recommendations for not only future research but for a renewed approach to greener
healthcare.
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CHAPTER 2

TYPES AND QUANTITIES OF LEFTOVER DRUGS ENTERING
THE ENVIRONMENT VIA DISPOSALTO SEWAGE REVEALED BY CORONER RECORDS
Overview
Pharmaceuticals designed for humans and animals often remain unused for a variety
of reasons, ranging from expiration to a patient’s non-compliance. These leftover,
accumulated drugs represent suboptimal delivery o f health care and the potential for
environmentally unsound disposal, which can pose exposure risks for humans and
wildlife. A major unknown with respect to pharmaceuticals as pollutants is what fractions
of drug residues occurring in the ambient environment result from discarding leftover
drugs. To gauge the significance o f leftover pharmaceuticals as potential pollutants, data
are needed on the types, quantities, and frequencies with which these drugs accumulate.
Absence o f these data has prevented assessments of the significance o f drug
accumulation and disposal as a contributing source o f pharmaceutical residues in the
environment. One particular source o f drug accumulation is those medications that
become "orphaned" by the death o f a consumer. A new approach to acquiring the data
needed to assess the magnitude and extent o f drug disposal as a source o f environmental
pollution is presented by using the inventories o f drugs maintained by coroner offices.

12

The data from one metropolitan coroner’s office demonstrates proof of concept.
Coroner data on leftover drugs are useful for measuring the types and amounts o f drugs
aeeumulated by eonsumers. This inventory also provides an aeeurate measure o f the
individual aetive ingredients aetually disposed into sewage by eoroners. The types of
questions these data ean address are presented, and the possible uses o f these data for
deriving estimates o f source eontributions from the population at large are diseussed. The
approaeh is proposed for nationwide implementation (and automation) to better
understand the significanee o f eonsumer disposal o f medieations. Note: This ehapter has
been previously published as Ruhoy and Daughton 2007.

Introduetion
Understanding the seope and magnitude o f medieation disposal is required for
providing: (1) more aeeurate and eomprehensive data for models used for predicting
amounts or concentrations o f active pharmaeeutical ingredients (APIs) introduced to the
environment, and (2) a better understanding o f the prescribing, dispensing, and eonsumer
consumption practices that lead to the aeeumulation o f leftover (unwanted or unneeded)
drugs and which then eontribute to human morbidity and mortality via poisonings
(Watson et ah, 2005). There are two major reasons that leftover drugs are not
immediately disposed: (1) inadvertent household accumulation (resulting from drugs
languishing unnoticed past their expiry), and (2) purposeful stockpiling (because the
consumer is awaiting a satisfactory means for disposal) (see Figure 1).
This chapter introduces a methodology for collecting data to provide evidenee-based
estimates on the types and quantities o f APIs disposed to the environment. While still
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rarely used, the records o f coroner offices for use in epidemiologic research has been

evaluated and recommended by Conroy and Russell (1990). Coroner offices in many
locales maintain detailed inventories o f medications remaining at sites visited for
investigation and acquisition o f decedents. Drug stockpiles can serve as a means o f
obtaining maximum and minimum ranges on the quantities and types o f drugs that might
have ordinarily been disposed by this subpopulation. These inventories also become an
accurate record o f the types and quantities o f APIs that are actually disposed by coroner
offices. This is the first time that an extensive dataset o f disposed drugs has been
compiled for a well-defined population whose sewage is known to be handled by
particular sewage treatment facilities. Such a dataset should permit calculations o f
average (or minimum) concentrations o f APIs introduced via sewage. This is proposed as
a general approach that can be widely implemented. The pieces o f data, namely, types,
dosages, and quantities of remaining pharmaceuticals, collected using this new approach
are useful for quantifying or estimating source contributions o f pharmaceuticals
introduced to the environment and which subsequently could play roles in ecological as
well as human exposure, via the natural or artificial recycling o f water.
Residues o f a wide array o f pharmaceuticals are known to occur as contaminants in
the environment (Daughton and Temes, 1999; Halling-Sorensen et al., 1998; Kolpin et
al., 2002). A major research gap continues to be an understanding o f the relative
contributions to these ambient residues resulting from their intended use (such as from
i

excretion and bathing) versus the direct disposal o f unwanted, leftover,medications. The
significance o f contributions from direct disposal compared with excretion remains

14

controversial, largely because there have been no easy means o f determining the
quantities o f medications that are directly disposed, for example to sewage or trash.
The topic of pharmaceuticals as environmental pollutants continues to foster
increasing discussion and debate. Various groups, including regulatory agencies,
independent organizations, water utilities, and public advocacy groups, have placed high
priority on determining whether the existence o f APIs in the environment, albeit at low
concentrations, pose exposure risks for humans or the environment (Pent et ah, 2006).
One o f the outgrowths o f this concern in the US has been increasing interest from local
and regional agencies in the implementation o f programs designed to take back
medications stockpiled by consumers, thereby obviating their disposal directly to the
environment. Several states, cities, and counties have successfully implemented both
single and recurring collection events for unwanted medications (IISG, 2007). The
intention o f these "take-back" programs has been to reduce the introduction o f APIs to
sewerage and trash, from where they can enter the environment as contaminants. The key
unknown with these pollution prevention efforts, however, is whether they can
significantly reduce the individual or overall loadings of APIs to the environment
(Daughton, 2007).
An additional development is the recent federal guidelines for drug disposal. In an
effort to combat the rising rates o f prescription drug abuse, the White House Office of
National Drug Control Policy (ONDCP, 2007) has established, along with the US EPA
and the FDA, the first Federal guidelines for proper disposal o f unused drugs. These
guidelines, released in February 2007, direct consumers to adulterate unwanted
medications by mixing with an unpalatable substance and then disposing into the
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household trash (except those few whose labels require disposal to sewage because o f the
acute risk of diversion resulting in human poisonings). While adulterating medications in
this manner does not remove the A PI’s potential to enter the natural environment, the
intent o f these reeommendations is to prevent purposeful introduetion of medieations into
sewage while also rendering them unpalatable for those who attempt to reclaim the drugs
from the trash for inappropriate use. The federal guidelines also suggest returning
leftover drugs to local “take-back” locations, when available. This demonstrates the
Federal government’s interest in reducing the availability o f drugs to those who seek to
misuse or abuse prescription medication, while also redueing environmental pollution.
Pharmaceuticals are ubiquitous eompounds that have the ability to alter innate human
physiological mechanisms. Studies o f these compounds as they occur in the environment
are unique in various ways. First, these compounds are often detected at such low
concentrations (ng L"') that detection is usually limited to more recent, advanced
analytical techniques employed at research laboratories (Daughton, 2007). Second, recent
studies (e.g., Heberer, 2002; Radjenovic, 2006; Snyder et al., 2006) have indicated
efficient and effective methods (e.g., ozone oxidation) o f removing, if not all detectable
amounts, a significant percentage o f the more commonly studied APIs; note, however,
that “removal” can refer to the structural transformation o f the API or it can simply refer
to the physical relocation or partitioning o f the API from the aqueous phase to the solids
(sludge) phase. It is important to note that most wastewater treatment plants (WWTPs) in
the US do not possess the resources required for the best available treatment technology.
Third, controversy remains over whether acute or chronic exposure to pharmaceuticals in
our water supply results in detectable human health effects. Finally, and with reference to
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the study presented here, while there have been a number o f studies that have measured

levels o f APIs and their metabolites in wastewater, there has been no ready source o f data
that characterizes the types and masses o f APIs disposed via flushing to sewage and
whether these amounts are significant with respect to overall environmental loadings
(Daughton 2007).
Chemical monitoring studies have provided evidence o f the presence o f drugs in the
aquatic environment (e.g.. Pent et al., 2006; Heberer, 2002; Hignite and Azamoff, 1977;
Hirsch et al., 1999), and less frequently in drinking waters, but the sources and their
correlations with disposed quantities have proved difficult to determine. There are no
datasets that elucidate categories and quantities o f drugs that are disposed at any
particular time. Coroner offices, however, consistently compile drug disposal data during
the ordinary course o f investigating and taking custody o f the bodies o f decedents for
each coroner case. A survey o f this inventory provides a snapshot and some insights as to
the potential extent o f unused pharmaceuticals and their disposal. The information
gleaned from these under-recognized databases can help guide the identification o f drugs
to be monitored in the environment and better target where pollution-prevention or
source-control efforts should be directed.
Often overlooked are other important possible uses from obtaining comprehensive
data on leftover drugs and their disposal. Such data could foster the optimization of
prescribing and dispensing practices within the healthcare communities, along with
improving communication with patients to improve their adherence to medication
regimes. This transformation, by reducing leftover medications, would lessen the
consequent need for disposal, and possibly improve healthcare outcomes (Daughton,
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2003a). In the ideal world, perfectly functioning prescribing and dispensing systems,
coupled with perfect medication adherence by the patient (while noting that one cause o f
non-adherence is unanticipated adverse effects), would lead to zero drug wastage and
completely eliminate the need for disposal o f leftovers. Although probably not a
realistically achievable goal, any progress in this direction might also improve the quality
of healthcare.
The presence of pharmaceuticals in our environment is by no means unexpected.
Pharmaceuticals owe their release to the environment to their universal and highly
dispersed but cumulative usage by multitudes o f individuals (Daughton, 2001). From
1993 to 2003, the number o f prescriptions purchased in the US increased 70% (from 2
billion to 3.4 billion) (Kaiser, 2004), while the population increased only 13% (from
257,782,608 to 290,796,023) (US Census Bureau, 2006). The elderly consume an everincreasing number o f medications - some prescribed to counteract the effects and
responses of other prescribed medications. At any given time, 40% o f those older than
65 years use five or more drugs, and 50% o f all adults in the US (greater than 18 years of
age) take at least one prescription medicine (Kaufman et al., 2002). In 2005, among the
300 most frequently prescribed pharmaceuticals in the US, more than 2.5 billion
prescriptions were written (RxList, 2007). Prescription rates for opioids,
benzodiazepines, diuretics, monoamine agonists, anti-infectives, and corticosteroids were
the highest among all the medications prescribed.
Unused pharmaceuticals not only pose exposure risks for both the environment and
humans, they also reflect lost opportunities for proper therapeutic treatment and wasted
healthcare resources. In the US alone, an estimated $1B (US) o f prescription drugs are
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discarded each year (Strom, 2005) from healthcare institutions such as hospitals,
pharmacies, hospices, and long-term care facilities; figures for consumers do not exist.
Although procedures are available in the healthcare sector (such as hospitals, pharmacies,
hospices and long-term care facilities) for the proper disposal o f unused pharmaceuticals,
especially for the low percentage that are regulated as hazardous waste, generally these
substances are simply disposed to drains (and sometimes to trash) or disposed along with
regulated medical waste (Burke and Smith, 2006). These unwanted and unused drugs
represent a costly wasted resource for the healthcare system and indicate the growing
problem o f what to do with unused and unwanted medications or how to minimize their
creation. With regard to public health, this wasted resource may reflect inefficiencies in
prescribing practices and may indicate sub-optimal delivery o f healthcare, impairing or
diminishing therapeutic outcomes. Unused, unwanted drugs in consumer homes
inadvertently accumulate past expiry or are stockpiled (awaiting disposal) and are
therefore available for those (including children) who seek to abuse them or who might
ingest them accidentally (Figure 1, end o f chapter). Unwanted drugs, moreover, represent
a source from where a spectrum o f biologically active anthropogenic chemicals can enter
the environment. That human health and the health o f the environment can be
inextricably tied (Daughton, 2003b) is demonstrated perhaps in no better way than the
fact that the non-optimum delivery o f health care is, in part, a contributing source for
pharmaceuticals in the environment, which in turn may play a role in affecting the
environment and, therefore, quality o f life.
Prior to this approach described for mining coroner data, the only means available for
obtaining inventories of drugs destined for disposal was from take-back events or from
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physical investigation o f municipal trash. Both are highly resouree intensive, and as a
consequence are o f limited informational value. Obtaining data from take-back events
requires the efforts o f a pharmacist (under the vigilance o f law enforcement) to identify
and record the identity o f the medication, the dosage o f the API(s), and the dosage units.
These data are already meticulously collected during the course o f coroner investigations,
requiring no additional work.
Decedent populations could be biased in terms o f age and health status. Many
decedents are younger and probably represent the norm in terms o f health and drug
consumption. The drugs inventoried during coroner investigations could therefore
possibly be biased in terms o f the types o f drugs or their formulations, and perhaps biased
somewhat high in terms o f the quantities on-hand (for those with declining health). In
contrast, the drugs returned at local take-back events held on sporadic schedules very
possibly represent accumulations over long periods o f time (where the consumer had
accumulated a backlog o f drugs for an entire household while waiting to eventually find
out how they could be disposed). This means that the quantities o f drugs initially received
from a particular individual during a take-back event may be biased high -n o t
representing the amounts that would be returned if take-backs occurred on a continual
basis; it is also very difficult to extrapolate to the general population. For the decedent
population, the types and quantities o f drugs on hand represent the types and amounts
that would be found at any point in time for a decedent. For take-backs, however, the
quantities o f drugs returned cannot easily be used to calculate population accumulation
rates because the quantities that any one individual returns could decline over time. Data
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would need to be collected over sufficiently long periods o f time to obtain representative
data.
Coroner investigations do not select for inherently biased populations - - namely
individuals who were necessarily purposefully saving unwanted drugs. Most decedents
had probably been living lives unconnected to any focus on accumulating drugs. In
contrast, the population attending take-back events may be biased in terms o f those who
have purposefully been accumulating leftover drugs while waiting to figure out how to
dispose o f them.
Another consideration with respect to coroner data is the ability to collect more
information regarding the individual, such as age, sex, patient non-compliance, illicit
drugs (usually available from police investigation reports), and location o f residence.
Location is important should it be desired to estimate quantities o f APIs that are
introduced to sewage within a particular sewage district [in order to calculate
concentrations or quantities entering a given Wastewater Treatment Plant (WWTP)].
Compliance is extremely useful to know in order to better design approaches to pollution
prevention, such as more vigilant and appropriate prescribing.
Attempts at identifying and quantifying the types and amounts o f wasted drugs have
often been inadequate in terms o f accuracy, consistency, and breadth. Most o f the
information amassed has been from various one-time local take-back events (CRG 2006).
Data collection from these events has never been standardized, and there is no current
consensus on the most efficient way to inventory the types and quantities o f drugs
received over the course o f these events. Often reported are just the gross weight and/or
volume of the complete, formulated medications, sometimes including the retail
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packaging (without note o f actual API content), because identifying and measuring the
types and amounts o f drugs was labor intensive and frequently cost prohibitive. The
Unused Medicine Registry (CRG Medical Foundation, 2006) was recently established by
the Community o f Competence organization in Bellaire, TX to collect information about
drugs remaining in the home. The Registry is designed to collect information from
community-based drug return programs (take-backs) on the medications received from
consumers. While the Registry demonstrates some important trends in unused
medication, the data received are from a variety o f events, many with different
organizational structures and different methodologies used to collect the data. Another
major limitation of data collected from take-backs is that the subpopulations o f those who
return their medications cannot be correlated with the WWTPs that receive their waste,
making calculation o f API masses introduced to known sewage flows inaccurate or
impossible. Other methods o f acquiring similar types of data generally focus on waste
from institutions such as hospitals and long-term care facilities, which are not necessarily
representative o f the general population.
The methodology described here allows for the identification and quantification of
the APIs actually disposed from a previously unrecognized but common source —coroner
offices. Comprehensive data on medications disposed within one metropolitan county,
Clark County, NV, during a calendar year were compiled. The information contained in
the greater than 1,600 records includes not only the type o f medication found, but the
i

number of pills remaining, the dosage amount o f each pill, the date d f the prescription,
and the prescription directions such as the frequency of the directed consumption. These
medications represented greater than 400 different active pharmaceutical ingredients.
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encompassing the more commonly prescribed cardiovascular and central nervous system
agents to the less often prescribed such as anti-retroviral medications. The complete
inventory o f medications identified by the Clark County, NV Coroner Office will be
published in future publications.
These data provide some insights and measures regarding the contribution to ambient
environmental residues o f human drugs that result from sewage disposal. If this type of
data were to be collected on a nationwide basis, the means for improving the practices for
prescribing and dispensing of drugs could eventually lead to minimization of the
accumulation o f leftover drugs. A major outcome o f this new methodology would be an
increased understanding o f the scope o f disposed pharmaceuticals. Such an understanding
could lead to new approaches for reducing drug diversion, abuse, and accidental
poisonings, as well for improving therapeutic outcomes at lower cost.

Background
It is considered standard protocol by most coroner offices in the US, as described by
the National Association of Medical Examiners (NAME, 2007), that when a medical
investigator from the coroner's office arrives upon the scene o f a decedent, following the
standard procedures regarding the approach to the body and the scene. The investigator
will then search for medications, prescribed in the name o f the decedent, present on the
scene, in case drugs may have contributed to the cause o f death. There are some cities,
however, where law enforcement services are called to the scene rather than investigators
from the coroner’s office; in these cases, the coroner’s office medical investigator plays
no role in analyzing or removing anything from the scene and therefore does not have
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any role in the disposal o f leftover medication - they simply receive the expired body.
There currently are no accessible statistics that describe how many cities primarily use
law enforcement instead of coroner services, nor is the process o f collecting and
inventorying medications standardized among them. However, a survey is under
preparation to effectively assess the prevalence o f coroner offices that operate under these
guidelines (Ruhoy, in preparation).
A death becomes a coroner's case when the decedent has either expired alone or the
death is considered suspicious by law enforcement. The majority o f the coroner cases are
due to those deaths that occurred without a witness present. The investigator at the scene
records the information found on the medication vial or submits them to Poison Control
Services for help in identification. This information includes the prescription number (as
labeled by the dispensing pharmacy), the date the prescription was filled, the name o f the
medication (generic or brand name), the dosage, the directions for taking the medication
as prescribed by the physician, the prescribed number o f pills (which refers to both
tablets and capsules but does not include powders, liquids or alternative drug delivery
systems), and the name o f the prescribing health care professional. The final and
important piece o f information recorded by the investigator is the number o f pills
remaining in the prescription vial. A facsimile o f a typical coroners’ site-investigation
record is shown in Figure 2 (end o f chapter).
Following the collection o f data on an inventory sheet, the investigator then disposes
o f the remaining prescription pharmaceuticals. This is done most often via the toilets at
the locations of the decedents and always done in the presence o f a witness. Occasionally,
the medications are disposed o f in the garbage o f the home, either because o f faulty toilet
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systems or at the request o f family. Disposal is manually recorded along with the
signatures o f the disposer (usually the investigator) and the witness (usually a family
member or a local police officer). These factors all contribute to ensuring a high standard
of quality for the collected data.
The medical investigators are “deputized” and, therefore, act as representatives o f law
enforcement. This is necessary due to US Drug Enforcement Administration (DEA)
enforcement o f the Controlled Substances Act (CSA) (US DOJ, 1970). The CSA was
enacted into law by the Congress o f the United States as Title II o f the Comprehensive
Drug Abuse Prevention and Control Act o f 1970. This law prohibits the transference of
any controlled substance from the prescribed individual to any entity other than law
enforcement (see summary in Daughton, 2007). The consumer is considered the end user
and cannot transfer the controlled medication to anyone, including a physician or a
pharmacist. All pharmaceuticals identified by the medical examiner are required to be
disposed o f by the investigator, as opposed to allowing family members to take
possession o f the leftover drugs. Law enforcement officers are permitted to seize
controlled substances. It is permissible, however, for consumers to return unused and
unwanted pharmaceuticals to their local police stations.
Medications collected and disposed o f by coroner offices are themselves a
measurable source o f drugs in the environment. O f more interest, however, is the fact that
these inventories provide information regarding the categories and dosage amounts of
medications that accumulate and require disposal. At the least, if local sewage flow rates
are known, coroner disposal data can be used to calculate minimum known introductions
to sewage for an individual water treatment plant or watershed; additional sources would
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include excretion and bathing, as well as disposal from a wide array o f additional sources,
including consumers (Ruhoy and Daughton, 2008). For the purposes o f the model
scenarios developed in this discussion, the assumption is that the sole source o f an active
pharmaceutical ingredient (API) in sewage would be from direct disposal by coroner
offices. At the maximum, these data could be used to estimate upper boundaries for these
introductions (by assuming similar drug disposal rates across a community’s entire
population, not just from the coroner). The empirically measured load for any given drug
targeted by a monitoring study o f sewage influent would fall below or near this imputed
upper bound if excretion were a minor source. An empirically measured concentration for
a drug that is extensively metabolized (i.e., resulting in excretion o f minimal parent API)
and that fell near the imputed maximum range would indicate the possibility that disposal
was a significant contributing source.
Knowledge o f the categories, types, and quantities o f drugs being disposed can help
guide the selection o f targets for environmental monitoring and for study o f the potential
impacts on both the environment and human health (from inadvertent exposure to
ambient residues from the environment). In this study, the disposed drugs were
introduced to sewage known to be treated by particular, locally serving WWTPs, making
possible the calculations o f minimum amounts o f APIs introduced to sewage. The data
can also be used, in conjunction with requisite demographics data, to derive virtual
predicted introduction concentrations (PICs) for disposed drugs (concentrations smoothed
I

over time), for the first time allowing an estimation o f the actual or estimated impact o f
drug disposal on total environmental loads o f pharmaceuticals.
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Furthermore, the data may provide valuable insights regarding use, nonuse, and

misuse o f medications, which can then serve healthcare practitioners in their approach to
treatments prescribed. The coroner data also provide some insight to what categories of
drugs accumulate due to patient non-compliance, and therefore which drugs have the
highest potential for accumulating unused, eventually requiring disposal.
Interpretations that could be derived from the data include patient compliance rates
and abuse rates. Patient compliance and adherence is an important issue in the medical
community, as it greatly impacts therapeutic outcomes and is a major factor in health care
cost (Foxhall, 2007; Haynes, 2006). While these terms are often used interchangeably,
non-adherence is when a patient attempts to follow the directions o f the physician but is
unable to adhere to all instructions for proper use and consumption. Non-compliance, on
the other hand, is when a patient, for any number o f reasons, willingly chooses to not
comply with treatment as prescribed by the healthcare practitioner. There remains a
subtle difference and that difference is often disregarded in the literature. This discussion
uses the words synonymously since the end-result is very similar.
Compliance is also a major factor leading to the accumulation o f drugs in households,
and therefore, has direct ramifications for the environment (because o f consequent
disposal). The rate o f compliance is frequently discussed in the medical and pharmacy
communities, and wide ranges o f rates (ranging essentially from 0% to 100%) are often
stated with little supporting data. A report released by the National Community
Pharmacists Association and Pharmacists for the Protection o f Patient Care states that
38% o f consumers questioned had forgotten to take a prescription medication, and 29%
o f those surveyed said that they had at least once stopped taking a drug before the
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prescribed period was over (NCPA, 2006). The same survey found that 74% of
respondents admitted to non-compliant behaviors including skipping doses, taking less
than the recommended dose, or forgetting to take medication. In a survey by Abahussain
et al. (2006), 25.8% o f the respondents reported self-discontinuation o f treatment
regimens. A persisting, unanswered question is the percentage o f accumulated, unwanted
medications that derives from non-compliant behavior.

Methods
Data as described were collected from the Clark County Coroner's Office (CCCO) in
Clark County, Nevada. The total available data were selected from the 13-month period
of January 2005 through January 2006 as this was the most recent accessible data for an
entire calendar year. In this period, there were 1,632 coroner cases having drugs that were
inventoried and therefore suitable to evaluate in this study. The most recent census for
Clark County estimates a population o f 1.7 million people (US Census Bureau, 2006).
Data were then entered into a spreadsheet, reviewed for accuracy by comparing computer
records with manual file records, and analyzed.
As indicated on the CCCO website, there were 13,761 deaths reported in Clark
County in 2005. O f this total, 10,135 deaths were reported to the Clark County Coroner.
The total number o f cases accepted as coroner cases was 3,393. Some o f these cases,
however, were not deaths in the home environment. For example, coroner cases include
traffic accidents or bodies found outdoors. For obvious reasons, these case files usually
did not include medication inventories. Certain other cases, while located in a home
environment, did not have any unused medications to report. Often these cases were

28

deaths o f minors or young adults. The 1,632 cases reviewed (48% o f the total coroner

cases) represent those cases that contained a medication inventory log. Fifty-eight o f the
cases reviewed were from January 2006. To consider the data on the basis o f a complete
calendar year, 1,574 cases therefore contained medication inventory logs during 2005.
The cases reviewed represent approximately 11% o f all 2005 deaths reported in Clark
County. Note that this frequency o f occurrence o f drug-inventory data may not be
representative o f the frequency at other locales, but would have no influence on data that
might be collected in other locales.
The 2005 death rate for Nevada is comparable with that on a national basis. In 2005,
the 13,761 deaths in Clark County’s population o f 1.7 million represented a rate o f 0.008.
In the US, during 2005, there were 2,432,000 deaths in a population of 297.8 million
(NCHS, 2006), also a rate o f 0.008%. This is significant in terms o f relating the
populations and extrapolating the data.
The data compiled by the coroner office in Clark County resides in handwritten
and/or digital notations recorded by case number. For this study, each case was reviewed
for data regarding pharmaceuticals located and disposed of. The listing o f the specific
pharmaceutical information (such as name o f drug, prescription dosage, prescription date,
and directions for use) is originally recorded on a written inventory sheet included in each
case file; a facsimile example is shown in Figure 2. The information is then entered as a
narrative parameter within the coroner database. However, not all cases had been entered
into the case database, often due to time constraints o f entering multiple medications
found in a particular case. Therefore, each case, including its inventory sheet and digital

29

file, was evaluated manually in order to compile all pharmaceuticals disposed during the

research period. Each paper file was reviewed for accuracy and thoroughness.
This information was recorded in an Excel spreadsheet, and masses o f APIs disposed
o f were calculated using the number o f doses identified and the dosage strengths
reported. The information was alphabetized by API name as well as sorted by
pharmaceutical category as listed in the Tarascon Pharmacopoeia (Tarascon, 2007).
It is important to note that sometimes the brand name was listed in the coroner
records as opposed to the generic name. For example, furosemide, an oft-prescribed
diuretic, was frequently listed as Lasix®. The data were scoured for these inconsistencies,
and all brand names were replaced with generic names for proper chemical distinction. In
addition, combination drugs, which are developed and prescribed with increasing
regularity, were separated into their component APIs. For example, Lottab® was entered
into the spreadsheet as both hydrocodone and acetaminophen, with appropriate dose
amounts applied.

Results

'

The 13-month CCCO dataset contained greater than 5,000 discrete entries,
representing on average a little over three APIs per decedent. Each entry represented a
single API from a medication identified at the scene. A medication is most often
identified by the label on the prescription bottle. In some cases, no pills were remaining
i

from a prescription, and the entry then showed zero doses disposed. As described above,
those medications that were dispensed as combinations o f APIs were separated in the
spreadsheet into their components. Therefore, one entry does not necessarily correlate
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with just one medication inventoried. Some representative data are presented here for
illustrative purposes.
The most prevalent method o f disposal for the CCCO was to flush the inventoried
medications into the sewage system. Greater than 92% o f the medications found at
decedent sites were flushed. Approximately 7% o f the medications were disposed o f in
the household trash o f the home o f the decedent. Less than 1% was incinerated by law
enforcement service. This latter disposal route usually occurred when loose, unidentified
pills were found. These pills would be collected and transported to the offices o f the
Coroner and subsequently identified by Las Vegas Poison Control and inventoried.
Following this, the Coroner would apply for a court order to dispose o f the drugs, since
the act o f taking them into possession then made these drugs evidence. The court order
would allow cremation o f the drugs in the possession o f the Coroner.
During the 13-month period o f this pilot study, at least 325,000 doses o f a wide array
of drugs were disposed o f into the sewage system by the CCCO; in Clark County, this
system is serviced by three tertiary treatment plants. This estimate does not include the
multitude o f other medication formulations (such as powders and liquids) and delivery
systems (such as inhalers, patches, and syringes). Powders and liquids were also disposed
o f into the toilet but were not quantified in this study. Inhalers, patches, and syringes
were disposed in the household trash and were not quantified in this study. The 325,000
doses (1 dose = 1 pill/tablet/capsule) represent greater than 102,000,000 milligrams of
APIs disposed o f into the sewage system over the 13-month period. These 102 kg are
specific to the route o f toilet disposal. Recognizing the assumption regarding the
similarities in death rates between Nevada and the country, it is not unreasonable to
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extrapolate these data to obtain an estimate o f at least 17.9 billion milligrams (17.9 metric
tons) of APIs disposed of annually into the national sewage systems by the deceased
population alone (mass disposed by CCCO multiplied by the ratio o f the US population
to the Clark County population).
The following two examples illustrate the utility o f the coroner dataset. First is an
API that serves as a contaminant archetype because of its frequency o f occurrence in
environmental monitoring studies - the anticonvulsant, carbamazepine (CBZ). The
second comprises the beta-blocker cardiac medications. Analogous data exist in the
dataset for 200 other APIs.
The anticonvulsant CBZ is considered the primary drug for partial and tonic-clonic
seizures and is also used in other treatments. While a low percentage (1-3%) o f CBZ is
excreted unchanged, another portion is excreted as conjugates, which can be hydrolyzed
back to the parent CBZ, once released to sewage (Bendz et al., 2005). Therefore, the
effluent concentrations often may not be much reduced from influent concentrations. The
efficiency o f CBZ transformation in WWTPs and in the environment is not high, leading
to widespread persistence of measurable ambient, environmental residues (Bendz et al.,
2005).
During the 13-month period o f the collected data, there were 1,755 tablets o f CBZ
identified and disposed o f in the homes o f the decedents. These tablets represented
307,300 milligrams (307 g) o f pharmaceutically active CBZ introduced directly into the
Clark County sewage system. Since the most common dose prescribed was 200 mg, it
would take roughly between 51,000 and 154,000 oral doses o f CBZ for excretion to
contribute the equivalent o f 1,755 tablets o f the pharmaceutically active CBZ disposed of
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by the CCCO (assuming an excretion rate ranging from 1 to 3%). The Clark County

sewage system has average sewage flows o f 144.4x10^ gal/day (MGD) (LVWCC, 2007).
Assuming a hypothetical, uniform and consistent daily disposal to sewage, a minimum
averaged concentration o f 1.4 ppt CBZ (see Equation 1) could be expected in the influent,
as well as possibly the effluent, from the disposal o f CBZ by the CCCO alone.
Equation 1:
(307 g/13 months) x (12 months/year) x (1 year/365 days) x (1 day/144x10^ gal) x (1
gal/3.7854 L) = 0.0014x10'^ g/L = 1.4 ng/L = 1.4 ppt CBZ in WWTP influent
It is important to note that in reality the disposal o f medications does not take place at
a uniform, constant rate, but rather episodically. This will result in plug-flows that have
higher transient concentrations; this is one o f the variables involved with fluctuating
levels in sewage (Daughton, 2007).
Assuming CCCO serves the entire Las Vegas basin, this population is served by the
Clark County Sewage District. The US Census Bureau estimates 1.2 million adults over
the age o f 18 in Clark County in 2005 (US Census Bureau 2007). However, more
specifically, and perhaps more accurately since not only are most prescriptions written
for older adults (a result of a greater incidence o f polypharmacy), there are approximately
183,000 people in Clark County over the age o f 65 (US Census Bureau, 2007). The
CCCO data derive from 1,632 cases (over the course o f 13 months) and represent
approximately 0.0089% o f this sub-population. This estimate can be used roughly to
correct the estim ate o f 1.4 ppt (in STP influent) to 157 ppt C B Z d isp osed b y the

proportion o f the sub-population aged 65 or older in Clark County.
The 1,632 cases represent approximately 307 g o f CBZ identified and disposed
annually. This is roughly 0.19 g o f CBZ per case. As explained above, these deaths
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represent 11% o f all deaths reported in Clark County in 2005. Assuming similar coroner
statistics across all 50 states, 11% o f all deaths in the country would be 267,500 yielding
a potential 50.8 kg o f CBZ being disposed nationwide on an annual basis just by coroner
offices.
For the second example, consider the |3-adrenergic blockers, commonly referred to as
bcta-blockers, which are used in the treatment o f hypertension, systemic, and ophthalmic
disorders. The compiled CCCO data set indicates almost 10,000 leftover beta-blocker
pills that were disposed of, translating into almost 900,000 milligrams (900 g) o f betaadrenergic antagonist APIs disposed into sewage.
By using the prescription date listed in the coroner records, dose-frequency
instructions, doses remaining, and the date o f death, compliance or noncompliance can be
ascertained. The data for beta-blockers represented an approximate 33% rate of
noncompliance among the decedents for all the medications listed in the inventory. O f
great clinical interest, in almost 70% o f those noncompliant cases, the cause o f death
listed by the medical examiner was the precise disease the unused drugs were intended to
treat. By contrast, the cause of death listed due to acute toxicity o f prescribed drugs,
which by definition does not include illicit drugs, was listed in 7% o f the cases.
The study decedents possessed an average o f seven prescriptions. These medications
were the same pharmaceuticals that are commonly prescribed in the general population
(RxList, 2007) and were not present in inordinate quantities. While one might expect that
I

those near the end o f life would be taking larger quantities of particular pharmaceuticals,
for example, opiates for pain, this did not appear in the CCCO data. The number of
hydrocodone prescriptions for this data set was 692 (which may be due to high
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compliance). This did not necessarily represent one prescription per case since often
more than one hydrocodone prescription was listed for a single decedent. While details
regarding the number o f specific pharmaceutical prescriptions per decedent will be
elucidated in future articles, this basic information can be used to assess the
comparability o f local, state, and national prescribing and dispensing practices. There
were an estimated 1.8 million hydrocodone prescriptions in Nevada during 2005
(Haynes, 2005), a state with almost 2.5 million people (US Census Bureau, 2007). In the
same year, there were greater than lOI million hydrocodone prescriptions written in the
US (RxList, 2007), a country o f almost 300 million people (US Census Bureau, 2006).
While the ratios o f prescriptions to population count in Clark County (42%) and Nevada
(72%) are higher than national figures (33%), they most likely represent the upper range,
and may be due to local practices and demographics. This information is valuable
because it serves to establish the relevance and representativeness o f the data with regard
to its overall representation of the US population. In addition, it may be easier to address,
and alter, prescription and dispensing practices on a local basis. Comparing local
prescription behaviors with similar localities and communities may provide information
and recommendations for more efficient, effective, and prudent prescription handling.

Discussion
The data collected from the records of coroner offices regarding the quantities and
disposal o f unused drugs can be used as a comprehensive and accurate data set from
which to derive a wealth o f information regarding the extent o f environmental disposal of
pharmaceuticals that span all therapeutic classes; some example applications for these
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data are summarized in Table 1. The data can provide insights to answer questions such
as, in what quantities are specific medications disposed of, and what categories of
medication are commonly found in the coroner offices inventories. The coroner inventory
is useful because it includes data on specific drugs with dosage information that were left
over following a death, and that are directly disposed into the sewage systems by the
coroner staff. The disposed dosage amounts could prove very valuable in better
understanding the sources and their relative contributions o f drug residues as measured in
STP influents or effluents. As additional water monitoring studies are conducted, this
information could be helpful in correlating water concentrations and usage patterns
among local populations.
The same dataset provides insight into noneompliant behaviors among the population
ineluding the abuse and misuse o f prescribed medications and prescription trends o f the
representative géographie area. Combined with the information on disposal, these factors
need further evaluation for various scenarios that would have an effect on ambient
environmental concentration levels, as well as indicating the efficiency o f prescribing and
patient education by medical care providers.
Further analysis can reveal those medications that accumulate at rates
disproportionate to their dispensed frequencies and those that accumulate at the highest
absolute rates and in the highest quantities. Data such as these would be useful, for
example, in indicating which drugs experience high non-compliance or are prescribed in
excessive quantities. With these data as a guide, it is possible to target these drugs.for
emphasizing better prescribing (or dispensing) practices, as well as more prudent disposal
practices. An additional use for this inventoried data would be to identify those drugs that
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have not been the target o f monitoring efforts, but yet exist in the coroner data at
significantly high rates. For example, greater than 80,000 milligrams o f lisinopril, an
angiotensin-converting enzyme (ACE) inhibitor, was disposed of. The ACE inhibitors
have never been routinely targeted in monitoring studies.
There are two major approaches for ameliorating the disposal issue - source control
and pollution prevention. The first would focus on an effective and environmentally
friendly way to dispose o f pharmaceuticals that go unused. The second reduces the size
o f the source by reducing the quantities o f medications that accumulate and which would
have then required disposal. The supply and distribution o f medications coupled with the
behavior patterns o f patients and physicians dictate the amounts o f pharmaceuticals
having the potential to accumulate. Patient noncompliance to treatment regimens and
physician prescription patterns could be addressed to better optimize patient care and
reduce accumulations. These approaches may help to limit the accumulation of
pharmaceuticals and reduce the ready source o f those drugs that are highly addictive and
which are abused, misused, or targets o f diversion.
Minimizing the need for drug disposal will need to bring together professionals from
the health care and insurance industries, government, environmental sciences and policy,
and engineering. The research described here, and to be delineated in upcoming
publications, begins to address some o f the long-standing uncertainties in science that
will need to be resolved. It also exposes other areas o f a complex web o f pharmaceutical
sources that are in need o f individual disposal strategies, and potential ways in which the
amounts o f accumulated drugs can be reduced. In addition, the research introduces a
source of data that has previously been overlooked - where a potentially large source of
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drags introduced into the environment is already being inventoried and cataloged. This
information is valuable for furthering discussions regarding human medication behavior
and also provides a basis for future research into determining what quantities o f APIs are
disposed, and which then serve as a source o f APIs that can enter the environment.
A project creating a unified network o f inventoried-drag databases from coroner
offices around the country could prove highly useful. Such an effort could first compile
existing coroner data, and then automate for future collection. These data could be used
to improve patient outcomes and reduce costs o f health care. In turn, improved
prescribing practices should automatically reduce the quantities o f medications needing
disposal. The purpose o f this work is to provide some examples o f the types o f inferences
and deductions that can be derived from coroner data. An overarching objective is to
catalyze consideration for adoption o f a more comprehensive version o f this approach on
regional or national scales.
Note Added: Soon after the conclusion o f the project reported here, the Clark County
Coroner Office began discussions with local hazardous waste transporters regarding the
feasibility o f removal and transport o f their collected leftover decedeht drags to
incinerator facilities. The intent is to cease disposal o f the pharmaceuticals into sewage.
These discussions were partly a result o f the information provided by this research
project, as well as the desire o f local water authorities to comply with the newly issued
federal guidelines. The CCCO hopes to develop a model for proper and safe disposal of
pharmaceuticals acquired by the coroner.

,
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Coroner drug inventories can be used to:
• Types and relative amounts o f APIs disposed
• Actual quantities o f APIs disposed
• Fraction o f APIs disposed by various routes (e.g.,
sewage vs. trash)
• Minimum limits on amounts o f individual APIs
disposed
• Putative maximum limits on amounts o f individual
APIs disposed
• Predicted concentrations introduced to STPs
Determine
• Relative significance o f disposal with respect to the
overall environmental occurrence o f an individual
API
• Those APIs for which disposal is insignificant with
respect to their overall environmental occurrence
• Those APIs for which disposal might play a significant
role in their overall environmental occurrence
• Those medications for which patient compliance rates
are low

Guide

Selection o f APIs for targeted monitoring in sewage
streams and the environment in specific geographic
locales
Recognition o f APIs that are being over-prescribed
Recognition o f medications with poor patient
compliance

Table 1: P otential A p p lication s for C oroner D rug Inventories
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CHAPTER 3

BEYOND THE MEDICINE CABINET: AN ANALYSIS
OF WHERE AND WHY MEDICATIONS
ACCUMULATE
Overview
Active pharmaceutical ingredients (APIs) from medications can enter the
environment as trace contaminants, at individual concentrations generally below a part
per billion (pg/L) (Daughton, 2002). APIs enter the environment primarily via the
discharge o f raw and treated sewage. Residues o f unmetabolized APIs from parenteral
and enteral drugs are excreted in feces and urine, and topically applied medications are
washed from skin during bathing. These trace residues may pose risks for aquatic life and
cause concern with regard to subsequent human exposure (Daughton, 2008).
APIs also enter the environment from the disposal o f unwanted medications directly
to sewers and trash (Bound and Voulvoulis, 2005). The relative significance o f this route
compared with excretion and bathing is poorly understood and has been subject to much
speculation. Two major aspects o f uncertainty exist: the percentage o f any particular API
in the environment originating from disposal is unknown, and disposal undoubtedly
occurs from a variety o f dispersed sources. Sources o f disposal, along with the types and
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quantities o f APIs resulting from each source, are important to understand so that
effective pollution prevention approaches can be designed and implemented.
Aeeumulation o f leftover, unwanted drugs poses three major concerns: (i) APIs
disposed to sewage or trash eompose a diverse souree o f potential chemical stressors in
the environment, (ii) Accumulated drugs represent increased potential for drug diversion,
with its attendant risks o f unintentional poisonings and abuse, (iii) Leftover drugs
represent wasted healthcare resources and lost opportunities for medical treatment.
The work presented here has four major purposes: (I) Define the processes, actions,
and behaviors that control and drive the consumption, accumulation, and need for
disposal of pharmaceuticals. (2) Provide an overview of the diverse locations where
pharmaeeutieals are used and aecumulate. (3) Present a summary o f the first cataloging of
APIs disposed by a defined subpopulation. (4) Identify opportunities fOr pollution
prevention and source reduction. Note: This chapter has been previously published as
Ruhoy and Daughton 2008.

Introduction
Pharmaceuticals uses, for both humans and animals, inelude therapy, disease
prevention, diagnosis, eosmeties, and lifestyle. Residues from hundreds o f widely used
aetive pharmaceutical ingredients (APIs) ean gain entry to the environment via a complex
network of sources and pathways, interspersed through numerous parts o f society. These
I

potential eontaminants make their way into the environment primarily as a result o f their
intended use - as caused by exeretion or bathing. Disposal o f unwanted, leftover
medications to sewage and trash is another source o f entry, but its relative signifieanee is
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unknown with respect to the overall concentrations o f APIs in the environment. Wildlife
and humans can then experience long-term or intermittent exposure to APIs as trace
pollutants, primarily via contaminated water and foods.
O f the research accomplished to date regarding sources, fate and transport, exposure,
biological effects, waste treatment, and pollution prevention, very little has been directed
at the role played by the APIs in the environment originating from disposal o f leftover
medications compared with APIs introduced into the environment through excretion and
bathing. Leftover, unwanted pharmaceuticals (both human and veterinary) tend to
accumulate after being set aside, stored, or forgotten — and this occurs at just about any
location where people live, work, or visit. Accumulated or stockpiled leftover
medications are eventually disposed either through formal collection programs (with
disposal generally at hazardous waste landfills or by incineration) or simply by the enduser discarding directly into sewerage or trash. During storage and imprudent disposal
(e.g., leaving leftover drugs visible and accessible to others), a leftover drug can be
inadvertently diverted to those for whom the medication was never intended. This can
lead to poisoning o f humans and pets, or can further abuse and addiction. Well-designed,
efficient disposal programs hold the potential for preventing unnecessary human (and
animal) exposure and poisonings, as well as for reducing environmental pollution.
Many factors cause medications to remain unused, creating leftover drugs that can
accumulate. A wide spectrum of forces underlies the generation o f leftover drugs, ranging
from inefficiencies and certain practices o f manufacturers, distributors, prescribers,
dispensers, and patients themselves. Although design o f environmentally prudent and
safe disposal programs is currently being pursued (Reid, 2007), much o f the need for
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drug disposal could be eliminated by focusing corrective actions on these major causes of
accumulation with the design and implementation o f pollution prevention measures. Such
practices would be part o f a larger program that oversees all the aspects o f unintended,
adverse consequences of medications. Such a program has been termed
pharmEcovigilance (Daughton and Ruhoy, 2008).
Leftover medications pose an aeute exposure hazard for both humans and the
environment. Opportunities are lost for optimal delivery o f healthcare, and valuable
healthcare resources are squandered. The likelihood also greatly increases for drug
diversion and environmentally unsound disposal. These latter two liabilities can pose
acute and chronic poisoning risks for humans and wildlife alike (Daughton, 2007).
This research focuses on two major aspeets o f the larger topic o f pharmaceuticals as
environmental pollutants: (i) the processes, actions, activities, events, and behaviors that
cause drug wastage (leading to accumulation and disposal), and (ii) the many and diverse
physical sources from which stored and accumulated drugs can enter the environment as
a result of disposal. Such information should prove useful for the design o f pollution
prevention measures that encompass a significant portion o f the life cycle o f medieations.
Presented here is the first comprehensive examination of the reasons that medications
accumulate and the many potential sources or locations from where leftover drugs are
disposed. Better understanding o f the many and varied origins and sources o f leftover
drugs will allow for the design o f pollution prevention actions best tailored to minimize
or eliminate these accumulations, and therefore eliminate or reduce the need for disposal.
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Background
The use o f human and veterinary pharmaceuticals for their intended purposes is
accompanied by a very complex network o f routes by which APIs eventually gain entry
to the environment or result in unintended direct exposures to humans and wildlife (see
Daughton, 2008, Figure 1; 2007, Figure 1). A holistic, integrated view o f the life-cycle o f
pharmaceuticals includes not just the intended uses o f drugs, but also their unintended
consequences. A broad spectrum o f unanswered questions surrounds the environmental
lifecycles of drugs (Daughton, 2004). The accumulation and disposal o f leftover drugs is
but one o f their routes to the environment. In contrast to excretion, however, this route o f
release is more amenable to moderation by environmental stewardship programs,
especially those designed around pollution prevention (Daughton, 2002, 2003a, b). To
design and gauge the success o f such pollution prevention programs, the origins and
sources o f drug release need to be defined, and the absolute or relative contributions o f
these sources to the overall loadings o f APIs in the environment need to be known. The
individual percentages probably vary dramatically among APIs and among the types o f
packaging (for example, unit-packaged pills are probably not frequently disposed via
toilets, whereas liquids are probably routinely poured down drains). In particular,
disposal could prove to be a significant source for those APIs that would otherwise have
been extensively metabolized.
O f the major sourees and routes by whieh drugs gain entry to the environment, the
types and quantities o f APIs introduced to sewage as an unintentional result o f their
intended use (primarily as a result o f excretion and bathing) are amenable to estimation
using modeling based on usage data combined with parameters such as pharmacokinetics

49

(portion o f parent API excreted unchanged) and known efficiencies o f removal from
sewage treatment; such an approach has been used by Kostich and Lazorchak (2007). In
contrast, gaining an understanding o f the types and quantities of APIs introduced directly
and purposefully to the environment by the disposal o f unwanted, leftover drugs has been
more problematic because o f a dearth o f comprehensive or reliable data. O f the total
loadings o f a particular API in the environment, it is unknown what fraction results from
drug disposal. Chapter 2 presented a novel methodology for obtaining comprehensive and
accurate drug disposal data at the community level by the use o f existing drug inventories
collected during coroner investigations. These unique data can then be used for a variety
of purposes (see also Ruhoy and Daughton, 2007).
Another important aspect o f drug disposal, and one that is elucidated further in this
chapter, is the location at which leftover, unwanted medications accurfiulate. Probably
more than for any other perishable, non-food item consumed by humans, medications are
used and stored at a vast array o f locations throughout society, including schools and
nurseries, hospitals, nursing homes, hospice care centers, emergency shelters,
humanitarian organization locations, doctor and dentist offices, public-use first aid kits,
veterinarian offices, farms, military bases, and prisons, among others. These products are
frequently prescribed, dispensed, or purchased in excess or are not fully consumed as
directed (e.g., as a result o f poor compliance among patients), leading to the
accumulation of unwanted, leftover drugs. A variety of other factors also promote drug
i

wastage; bulk packaging of certain OTC drugs in quantities that cannot be consumed
before expiry is one example. These factors have been categorized by Daughton and
Ruhoy (2008).

50

Unused pharmaceuticals pose unknown risks for the environment and take a toll on
human health. Based on data obtained in 1999 from a series o f retirement communities,
Morgan (2001) roughly estimated that the annual value o f wasted medications just for
adults older than 65 years in the US could exceed $1B; this represented 2.3% o f total
medication costs. The accumulation o f non-utilized pharmaceuticals designed to treat
human maladies as well as to treat and care for both domestic and farm-reared animals is
emblematic o f a society-wide problem that affects both human and ecological health. It is
also one whose prevention could lead to immediate benefits for both.
The existence and extent o f unused pharmaceuticals could be adopted as a direct
measure o f non-compliance and poor adherence by the patient population. Noncompliance is often a significant factor in reducing the physician’s ability to treat and can
lead to poor therapeutic outcomes. The collective volumes o f excess and unused
medication can lead to unintentional pharmaceutical poisonings o f children (resulting in
morbidity and mortality), facilitate abusive use, and promote emerging social problems
such as teenage "pharming" (the theft and communal sharing and abuse of
pharmaceuticals by teenagers) (SAMHSA, 2007). In addition, the subsequent imprudent
disposal of unwanted drugs via domestic trash (e.g., in unsecured containers) encourages
and facilitates their reclamation by others (especially addicts) for non-medical purposes.
A better understanding of medication usage could lead to the design o f processes that
could reduce or eliminate the very need for drug disposal. Two aspects must be
considered; (I) the factors that lead to the generation of leftover, unwanted medications,
causing them to accumulate unused, eventually becoming wastes, and (2) the many and
varied locations and sites in society where medications accumulate (the relative
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significance o f each source of accumulation is currently not known). The first step is to
catalog the sources and assess why drugs accumulate at these locations.
A major question is whether implementing any number o f pollution prevention or
stewardship measures could control the disposal o f drugs. What causes or drives the need
for disposal, and can the incidence or magnitude o f disposal be better understood and
reduced or eliminated?
Note that the current approach to preventing pollution from drug disposal is to
implement various means for collecting leftover drugs and disposing o f them in the most
prudent manner available (primarily as hazardous waste) (Glassmeyer et al., 2008). For
those countries (e.g., Australia, Canada, France, New Zealand, Sweden, UK) having
formal collection programs for unwanted drugs (those no longer in the commercial
distribution/sales system), the most common approach is for consumers to return their
medications to local pharmacies; for collection practices in the US, see discussion o f
Glassmeyer et al (2008) and examples cited by IISG (2007). These “down-stream”
approaches are generically termed consumer "take-back" or "return" programs. In the US,
the design o f take-back programs is much more complicated, as medications cannot be
returned to operational pharmacies (unless a formal FDA recall has been issued); several
federal regulations currently make any type o f universal collection program extremely
complex and inefficient (see background presented in Daughton, 2007). This, coupled
with the growing imperative in the US to prevent drug diversion, prompted the White
House Office o f National Drug Control Policy (ONDCP, in conference with the FDA and
EPA) to implement guidanee for consumers for disposing o f drugs in a manner that
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reduces entry o f APIs to the environment while also protecting public (and animal) health

by minimizing diversion and accidental exposure (Daughton, 2007).
Regardless o f whether efficient collection programs can be developed for public use,
none will ever capture all medications that accumulate as wastes; no type o f disposal
process (whether landfilling as hazardous waste, incineration, or other type o f complete
destruction) is free o f the potential to generate hazardous by-products or release
pollutants in the future; and all have energy costs for transportation, storage, or
destruction. Instead, the optimal approach could be to prevent the need for disposal in the
first place - an “up-stream” approach that maximally protects the environment and at the
same time has the potential to improve health-care outeomes, reduce healthcare eosts, and
lessen the ineidence o f morbidity and mortality caused by human (and animal) exposure
to unsecured, unwanted drugs.
Numerous factors play roles in the accumulation o f drugs by end-users, whether they
are healthcare professionals, physicians, patients themselves, veterinarians, farmers, or
humanitarian relief workers. Some o f these factors are expiry, patient non-compliance,
and over-prescribing or excessive purchase; these have been summarized by Daughton
and Ruhoy (2008). Patients will discontinue taking medication due to, among other
reasons, intolerable or adverse effects, inconvenience in dosing schedule, a change in
therapy as prescribed by their physieian, forgetfulness, or even a poor pereeption o f the
severity o f their illness. Expiration is an oft-cited reason for accumulated drugs; however,
other numerous factors play a significant role (Pound et al., 2005). Poor adherence and
non-eompliance continues to be a major source o f public health concern (DHHS, 1990).
Significantly, the numbers o f consumers who do not follow medication regimens in the
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u s continue to be substantial, and addressing the causes could improve outcomes and

reduce morbidity and mortality (Bosworth et al., 2006; O ’Donohue and Levensky, 2006).
Sites o f drug accumulation extend far beyond the household medicine cabinet. Some
drugs are simply forgotten by consumers at a distant location (i.e., hotels, workplace, and
hospitals) and some are intentionally abandoned. Physician and dentist offices have
supplies of drugs on hand for intra-office procedures and sample dispensation. However,
some areas o f substantial drug wastage are independent o f the individual consumer as a
patient. These locations are associated with the demands and expectations o f the public
for the easy accessibility and availability o f medications. Public buildings, vacation areas
and marine vessels, and societal institutions such as prison systems and military bases are
all locations where drugs are stored in significant quantities in case the need arises. This
prophylactic approach increases the probability o f eventual expiration or simply non-use
o f the medications, thus necessitating their disposal.
The effort to address unused pharmaceuticals must examine all aspects o f licit drug
use and non-use. While consumer non-compliance is a significant factor, a strategy to
combat pharmaceutical waste should include preventative measures that encompass all
facets o f drug accumulation and waste.
An overview o f the diverse spectrum o f locations where drug buildup and eventual
disposal could occur is presented in Figure 3. It begins with the actual production o f the
pharmaceutical and traces the many places a drug may end up in following its purchase,
I

whether by prescription, over-the-counter, or by other means such as the gray market.
Each rectangular box shown in three dimensions in the flow chart represents a particular
site where accumulated human and animal medications might be found.
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For each location represented, diseussion is presented on where drugs ean reside,
possible causes for their accumulation at each particular site (e.g., expiry, overpreseribing, ete.), the method by whieh they aeeumulate (e.g., abandoned, orphaned,
stockpiled), and the problems posed by their aeeumulation (e.g., diversion, disposal, ete.).
Leftover drugs ean indieate medieal therapy was never eompleted, the medication
was the ineorreet choiee o f treatment, or that healtheare resources have been wasted. The
aeeumulation o f these leftover drugs ean further lead to or promote diversion to others,
resulting in drug abuse or purposeful human poisonings, or aeeidental poisonings in
humans (espeeially ehildren and the elderly) or pets beeause o f unseeured stoekpiling.
Eventual disposal o f the aeeumulated drugs may maximize the introduetion o f APIs to
the environment by eireumventing natural physiologieal proeesses that ordinarily might
have reduced their amounts via exeretion. Disposal may also result in aeute wildlife
poisonings (Daughton, 2007).

Diseussion
The origin o f all pharmaeeutieals is probably the simplest part o f the puzzle.
Pharmaeeutieals are manufaetured and produeed within faeilities owned or eontracted by
the individual pharmaeeutieal eompany. Following their manufaeture and produetion, the
drugs are transported to those entities that are then eharged with distribution o f the drugs.
These entities inelude both traditional briek-and-mortar pharmaeies and online eeommeree pharmaeies (some o f whieh operate illegally as “rogue” pharmaeies), and
distribution eompanies (often a subsidiary o f the pharmaeeutieal eompany itself);
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distribution companies stock other locations that may manage their own internal
pharmacies, whieh may themselves become points o f aeeumulation.
Currently, database and inventory technology allows for very efficient manufaeture
and distribution. Manufacturing companies are able to accurately estimate demand and
potential orders from their various customer retailers and wholesalers (Smith, 2007). This
allows them to produce exactly what is needed, when it is needed, and therefore produce
very little, if any, unused and unwanted medieations that ean accumulate. For a
diseussion on waste generation during the medication produetion process itself, whieh is
not a topic o f this discussion, see Velagaleti and Bums (2007).
The following discussion describes and evaluates: (1) the factors that lead to the
generation o f leftover, unwanted medications and (2) the many and varied locations and
sites in society where medications accumulate and from where they are subject to
disposal.
Actions designed to control the many factors that lead to dmg wastage and
accumulation clearly could help in reducing the types and quantities o f APIs that are
eventually introduced to the environment by way o f disposal. Note that while these
factors can also play roles in increasing the unintended release o f APIs to the
environment via excretion (improving patient compliance is one example), a wide
spectram o f other factors contribute more to the over-usage o f dmgs, resulting in the
unnecessarily higher excretion rates o f APIs. Many o f these factors have been
summarized by Daughton (2003 a, b); two examples inelude the manufacture o f raeemic
drags (where only one optical isomer is the therapeutic entity) and the use of
unnecessarily high doses and durations o f treatment (which often are established
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expressly for clinical trials in order to maximize the chances o f favorable outcomes but

which are never reevaluated or adjusted downward once the drug reaches final approval).
In fact, downward-adjustment o f doses by the patient (self-regulation) is a major factor in
“non-compliance,” and is caused by patients’ concerns regarding the medications
themselves (Pound et al., 2005).
Figure 4 demonstrates the many factors that influence drug usage - - and therefore
pharmaceutical wastage and accumulation. Identifying and assessing these parameters is
an important first step in recognizing the points where pollution prevention efforts could
be designed and implemented.

Factors Leading to the Generation o f Leftover, Unwanted Medication
Prom otional
York University (2008) researchers estimate the US pharmaceutical industry spends
almost twice as much on promotion as it does on research and development. Promotional
items and programs put forth by both pharmaceutical sales representatives (“sales reps”)
and manufacturers and distributors target both the general population or specific sub
populations and carry a positive message with regard to the use and benefits of
consuming prescribed pharmaceuticals. Manufacturers, distributors, and sales reps use
various approaches for prom otional to induce, entice, or convince physicians and other
healthcare professionals o f the effectiveness and the appropriateness o f prescribing their
drug to a particular patient population. These prom otional can be in the form of
advertising in medical journals, continuing medical education (CME) credits in exchange
for participation in a marketing program, and hosting various conferences, meetings, and
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workshops. Furthermore, an aggressive campaign o f “sampling” (providing sample
packages o f the medication at no cost to the physician) and “detailing” new, as well as
older, products can influence the extent to which a healthcare professional will consider a
drug product in treating a particular patient and/or disease.
Consumers and physicians both report that prescription drug advertisements are
increasingly influential. Surveys o f patients and physicians have concluded that patients
have asked their doctor about a medication solely as a result o f direct-to-consumer (DTC)
marketing, and physicians then consider prescribing such medications as a result o f the
patient’s request (Rosenthal, 2003). It is probable that DTC advertising brings more
patients into a doctor’s office seeking a prescription for a particular drug (Donohue and
Bemdt, 2004).
Concerns regarding conflicts o f interest - - for example, a particular manufacturer
hosting a CME course (which physicians and other professional are required to obtain on
a yearly basis in order for their practicing license to remain in effect) - - have been
discussed by various law and health groups but no consensus course o f action has been
reached. If these promotionals were limited and regulated, there would be much less
direct interaction and correspondence between those that produce and sell the drug and
those who can alter its rate o f prescription and, hence, consumption. Indeed, the recently
reauthorized Prescription Drug User Fee Act (PDUFA) provides greater authorization
and resources for the FDA to evaluate and assess the safety o f new medications as well as
i

public advertising (US FDA, 2007). Furthermore, several academic rhedical centers
across the country are instituting policies o f their own with regard to the relationships
between doctors and relevant industries. For example, the University o f Pittsburgh
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School O f Medicine has established a program that provides for the prohibition o f gifts
and free lunches, addresses faculty speaking and consulting involvements, and disallows
the presence of pharmaceutical representatives from patient areas
(http://www.coi.pitt.edu/IndustryRelationships/index.htm) (also see: Tregaskis, 2008).
Counteracting Promotions
Counter-promotion involves programs and interventions to teach health professionals
or students to critically assess drug promotion, i.e., to teach health professionals how to
interact with sales representatives and interpret promotional information. Norris et al.
(2005) describes programs that are intended to question the claims made by drug
manufacturers in advertisements and educational materials directed at both patients and
physicians. The effect o f these counter-promotional activities is still unknown for they
are still far outnumbered by the promotional programs. In the US, the American Medical
Association has guidelines about gifts from the pharmaceutical industry incorporated in
its Code o f Ethics (http://www.ama-assn.org/ama/pub/category/5689.html). These
suggest that gifts to doctors should primarily benefit patients and should not be of
substantial value. Further guidelines for regulating interactions between healthcare
practitioners and student doctors are needed to establish positive and beneficial
relationship with regard to the proper use and prescribing o f medications.
Prescribing
Prescribing medications to treat disease is not a simple and straightforward procedure.
There are many factors and considerations, not all o f which are justified by the literature
(especially by evidence obtained from double-blind randomized controlled trials), that
influence decisions to prescribe and what to prescribe.
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As already discussed, DTC advertising has a direct effect on the knowledge base, and
therefore the perspeetive and desires, of a patient. A doetor may be persuaded to eonsider
a speeifie medication in the face o f an ardent patient. In addition, if a physician were to
disagree with a patient’s request and preseribe an alternative medieation, this may affeet
the adherenee o f the patient to the medieation, as well as adversely affect the relationship
between physieian and patient (Pound et al., 2005; van Dulmen et al., 2008).
Direet-to-physieian marketing may play a role as well. Pharmaeeutieal manufaeturers
not only advertise to physicians via conventional methods (i.e., medical journals), but
also dispatch representatives of the eompany to regularly visit and educate physicians,
physicians-in-training, and office staff on their products - both old and new. These visits
(referred to as “detailing”) often inelude boxes o f free samples (referred to as
“sampling”) of the pharmaeeutieal produet as well as meals and marketing trinkets sueh
as pens, elipboards, and eups. Human nature as it is, it is easy to believe this
eommunieation style may play a role in the physieians awareness and knowledge of
medieations to be used to treat a partieular ailment. Manehanda et al. (2005) outlined the
various researeh on physieian and patient learning about drugs.
Optimal prescribing behaviors are complicated and time-eonsuming. While much of
medicine is practiced using algorithms and protoeols, often there is not one perfect
method of treating a chronie ailment, and eaeh patient needs to be regularly monitored
and managed. Genetic medicine (sometimes ealled “effieacy pharmaeogeneties”) is
teaehing us that each individual may have a different response to treatment as well as a
different eourse of disease. Drugs ean have many polymorphie meehanisms and result in
various physiologieal efleets and changes in different individuals (Foxhall, 2008). Yet
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treatment is often arrived at based on the conventional generic methods o f treatment o f a
disease as well as experience o f the physician with beneficial responses in other patients.
Regardless, without careful adherence to evidence-based medicine coupled with
individualized therapy and treatment, there is the potential for increased misuse,
mismanagement, and non-compliance with the medication.
Dispensing
Dispensing practices can affect medication usage. Dispensing refers to the method
and form by which a prescription is filled for a patient. Many pharmaceuticals are offered
in multiple forms - pill (which may be swallowable, chewable, or sublingual), liquid,
intramuscular injection, spray (which may also be used intraorally or intranasally),
creams or gels (dermally or intravaginally), suppositories (intravaginal or intraanal),
delivery devices (e.g., patches, intravaginal rings), aerosols (inhalation), or drops (eye or
ear); each o f these can pose different challenges with regard to disposal; used delivery
devices, in particular, can contain large amounts o f unchanged API. The form of drug
delivery can greatly affect a patient’s perception, willingness, and comfort in consuming
the medication. In addition, these forms can be prescribed and dispensed in different
quantities and using different methods. For example, chronically used drugs can be
prescribed in quantities sufficient for one course (with approved refills) or multiple
months (normally 90-day supply). Indeed, many pharmacy chains have promotions that
encourage increased purchase o f certain medications by offering lower prices for a 90day supply or by offering additional OTC medications at drastically reduced prices.
While certainly this is a convenience to the consumer who will theoretically not have to
travel to the pharmacy as often to retrieve prescribed medications, the larger supply
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stored in their homes increases the quantity o f unused medication in the case o f altered
treatment by their doctor or in the event o f their death. Indeed, some mail-order programs
send automatic refills o f 90-day supplies, leading to a continuing accumulation o f unused
medications upon a patient’s death.
Some medications are dispensed using methods that are intended to improve
medication usage. For example, birth eontrol pills, usually some combination of
estrogens and progestagens, are dispensed in unit-dose paekaging. This serves to assist
the user in adhering to the onee-a-day regimen. Unit-dose dispensing was originally
designed for hospitals to help reduce medieation dispensing errors. However, there are
some medieations that are preseribed in the out-patient setting in unit-dose paekaging.
The commonly prescribed “Z-Pak” (azithromycin) is prescribed in a pack of individually
wrapped tablets - each corresponding to a day o f the week, whieh is the extent of the
course o f treatment. Methylprednisone, a steroid used to treat chronic inflammatory
diseases, ean be prescribed in unit-of-use paekaging (Lipowski et al 2002) to encourage
proper weaning o f the patient from steroid use and avoid the complieations o f incorrect,
abrupt discontinuation. Technology for pharmacy repackaging o f bulk drugs in unit-dose,
unit-of-use, or multi-dose strips, together with day and time reminders (ealendar labeling)
are now available (as one example, see Parata Systems:
http://www.parata.eom/adhere/index.php).
Finally, dispensing of medication may sometimes be a eonfusing task in light o f the
I

many drugs that have similar sounding (and similar spelled) names. Barbella (2008)
reports that greater than 1,400 commonly prescribed drugs are implieated in drug errors
due to similar looking drugs or similar sounding names. This is often attributed to poor
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phone communication, poor facsimile quality, and poor penmanship on the part o f the
physician. Dispensing incorrect drugs can lead to pharmaceutical accumulation from
cessation of therapy due to poor response or the awareness of the error. Much o f this
confusion could be eliminated with widespread adoption o f electronic prescribing (“eprescribing”).
Non-Adherence and Non-Compliance
Non-adherence and non-compliance to prescribed treatment regimens is a significant
and widespread public health issue. Poor compliance and adherence continues to thwart
and retard efforts by healthcare practitioners to effectively and efficiently treat symptoms
and progression o f a wide spectrum o f diseases (NCPIE, 2007).
Research on compliance indicates a wide range o f non-compliance rates. Reported
non-compliance rates are speeifie for the disease being treated and the treatment itself.
For example, there is a higher incidence o f non-compliance for clinical depression and
for drugs that are prescribed for long-term treatment o f a chronic disorder. The World
Health Organization’s (WHO) 2003 report on adherence to long-term therapies states that
50% o f patients treated for chronic diseases in the US do not take their medication
properly (and a portion o f this is from failure to complete a course o f treatment), 30% o f
all refillable prescriptions are never filled, and 17-20% o f all new prescriptions are never
filled. While failure to fill or refill a prescription does not add to the accumulation o f
leftover drugs, it is possibly an indirect indicator o f failure to complete the prior
prescription or failure to fully consume free samples; it might also, however, simply
reflect a physician’s recent change in treatment, which was the most frequent cause of
returned drugs reported by Langley et al. (2005).
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Certainly the important factors associated with non-compliance that have been
identified are the severity o f the condition, salience o f the condition, and cost and
misconceptions regarding the therapy. Additional reasons why patients intentionally and
unintentionally cease treatment are varied as well. They include drugs with difficult or
awkward delivery systems (i.e., intramuscular or subcutaneous injections), adverse and
side effects, numerous psychosocial factors (e.g., fear of reliance or addiction), and even
sensory aversion. Worthington (2007) discusses the positive effect on compliance from a
drug’s aesthetics, such as its taste, smell, appearance and touch. Pound et al. (2005)
provide a thorough synthesis o f much o f the extensive literature on why patients resist,
avoid, ignore, forget, or alter directions for prescribed medications. The reasons are
countless and highly complex - as evidenced by the fact that non-compliance persists in
being an extremely perplexing and refractory problem faced by medicine. The critical
importance o f better understanding and addressing the numerous aspects o f noncompliance are emphasized by Rosenow (2005), who has referred to it as the “sixth vital
sign.”
Patients may decide they do not really need the medication due to misjudgment of
their health status. This is a difficult obstacle, as many factors can lead to confusion.
Misjudgment o f health status and the need for a medication can also result from diseases
that do not exhibit obvious signs or symptoms; this can be a disincentive for continued
treatment. There also may be a breakdown in communication between the prescriber and
the patient. While physicians may believe they have explained disease and relevant
physiology o f disease and drug mode o f action, in reality, patient may not understand and
become fearful, intimidated, or too anxious to ask the appropriate questions. Another
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reason for poor perception is the overall patient-doctor relationship. Adherence partly
depends on the prescriber’s ability to communicate the need and utility o f the intended
treatment. This is turn would depend on the patient’s perception o f the physician’s
concern, sincerity, and competence.

Locations and Sites in Society Where Medications Accumulate
First-Aid Kits
First-aid kits are probably present in nearly every public building. The Occupational
Safety and Health Administration (OSHA) require first aid kits to be readily available to
the public. Therefore, depending upon the size o f the location and the estimated public
traffic, there may be multiple kits present in the building at any given time. First-aid kits
are no longer simply bandages, ankle supports, and some gauze. Today, any consumer or
business organization can purchase first-aid kits that contain anti-diarrheal medications,
antiemetics, antihistamines, analgesics and antipyretics (e.g., NSAIDs, ibuprofen,
aspirin), antiseptics and biocides (which include antibiotics), cold tablets, cough syrups
and drops, antacids, as well as medication for motion sickness, menstrual cramps, and
stomach upsets. First aid kits are also ubiquitous at a wide spectrum o f other venues, such
as athletic facilities, camps, all forms o f transportation (cars, trucks, trains, boats,
airplanes, etc.), and travelers’ suitcases.
First-aid kits can be specific to the type o f institution in which they reside. For
example, Henry et al. (2006) recommends a school first-aid kit for asthma. Given the
increasing incidence o f asthma diagnoses in children, it is most certainly prudent for
educators to be familiar with the disease, it signs, and its management. The recommended
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“asthma first-aid kit” includes a bronchodilator agent. Since first-aid kits are usually used

sporadically, their contents often reach expiry. Furthermore, kits often must be stored in
locations that experience high temperatures and therefore their contents can reach expiry
very fast. Kits supplied by companies are routinely purged o f expired contents, while
others are replenished on an ad-lib basis. Regardless, the expired drugs are disposed by
kit-provider personnel usually via the sewerage (personal communications).
Physician Samples
Dispensing and use practices contribute directly to the generation o f leftover,
unwanted pharmaceuticals and may therefore provide opportunities for reducing the
quantity o f waste. One practice that is often overlooked, and often considered only
beneficial to the patient population, is the use o f physician samples. Samples, often called
“starter packs,” are specifically packaged samples o f drugs provided free by
pharmaceutical representatives to doctors (a practice termed “sampling”), often as part o f
a marketing strategy or as a means o f gaining access to the doctor. The intention is to
provide patients with a “starter” supply that will serve to treat in the interim o f receiving
the prescription at the physician’s office and until the prescription is filled at the
pharmacy. It is also considered a cost-saving measure since a sample sometimes provides
the entire course o f a short-term treatment or the course o f a testing period to assess how
the patient will respond to the drug before a full prescription is given (thereby avoiding
the prescribing o f larger quantities that might otherwise never be fully consumed).
I

Firm figures regarding the dollar value o f promotions in the US are not available. In
1999, drug companies gave doctors free medications worth more than $7.2B at retail
(nearly 10% more than the year before) (Petersen, 2000). The most current analysis.
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however, indicates that promotions in 2004 alone may have a market value ranging up to
$57.5B, or roughly $61,000 per physician in the US. Samples alone may represent about
$15B (Gagnon and Lexchin, 2007).
Samples have a number o f negative aspects, including personal use by prescribers and
their families, creation o f bias on prescribing habits for newer more costly agents, and
inappropriate record keeping regarding delivered and dispensed samples (Pai, 2000).
According to an American Medical Student Association report, the use o f samples is
associated with an influence on the prescription choices and behaviors o f the physician
(Vahia, 2007). Studies have demonstrated that the availability o f free medications is
considered by physicians when deciding upon a treatment regimen for a patient (Groves
et al., 2003). Such an effect on physician prescribing behavior would most likely serve to
sustain or expand the use o f sampling practices.
Physician samples represent opposing forces with regard to medication waste. On the
one hand, they can eliminate the dispensing o f larger quantities o f medication that may
have gone unused. They also certainly do provide treatment and economic benefits to the
patient. But on the other hand, they have the potential o f being a significant source of
unused pharmaceutical accumulation at the physician’s office or other healthcare
facilities and have an important potential for drug diversion (US DOJ, 2006). Not only do
the sample drugs remain unused and eventually expire in physician offices, they can
accumulate in the possession o f the patients as well. Physicians have no incentive to
decline sampling, often accepting all that are offered during detailing. At the same time,
patients have little incentive to decline the offer o f free samples from the physician, even
if they doubt they will ever use them. There is no requirement for physicians to maintain
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an inventory and therefore, as opposed to pharmacies, there is no real measure o f how

many samples are required for the number o f patients and types o f maladies seen in a
particular physician office. Consequently, samples will go unused and will eventually
expire in the physician’s sample closet. Pharmaceutical representatives do not accept the
return o f the samples, so they must eventually be disposed o f by the office. The disposal
will most likely be via the trash because the packaging (which is usually o f unit-dispense
design) would impede easy and convenient disposal via the sewage system. Few
published studies have assessed the extent o f accumulation o f expired sample medication
or the means of disposal by physician offices. In a single Canadian study, the population
of a single hospital was invited to return medications over a 2-day period, during which
time 47 kg o f medications were collected from 25 people (Nguyen et al., 2002). Over
87% o f the wholesale value of the collected medications came from physician samples
(valued over C$1,400 per physician); the bulk o f these samples were medications for
treatment o f cardiovascular, CNS, and women's health. At least in one instance, the
"Code of Marketing Practices" for Canada’s Research-Based Pharmaceutical Companies
(Rx&D, 2004), guidance does exist for the disposal o f "clinical evaluation package"
(CEPs): "Companies are responsible for making sure that all excess and/or expired CEPs
o f their own manufacture are returned to the company’s storehouse or head office."
When samples are dispensed to patients they too may be destined for accumulation
and eventual disposal. Samples are given so that a patient may “try out” a medication,
often with unclear instructions. This unclear directive compounded by the distinct
difference o f a physician’s formal “prescription,” in that it is often given in random
amounts, may prompt the patient to not necessarily consume as directed. In fact, sample
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packages usually do not have directions on how to take the drug as opposed to the labels
on dispensed medications. Patients may not understand how to properly consume the
drug and may therefore be discouraged to use them. These unused drugs accumulate in
household medicine cabinets and may be accessible to others for whom the medication
might be contraindicated. While there is no research regarding the extent to which drug
samples accumulate, local coroner data (Ruhoy and Daughton, 2007) here revealed the
presence o f unused sample packages with almost 5% of the decedents.
Long-Term Care Facilities
Pharmacists and other healthcare personnel employed by long-term care facilities
(LTCFs) have expanded responsibilities with regard to dispensing pharmaceuticals to
residents (and in disposing o f leftovers). In addition to providing chronic maintenance
medications on a daily basis to most, if not all, facility residents, personnel must be able
to supply drugs in acute (i.e., pain control, agitation) and emergency situations (i.e.,
advanced cardiac life support), stock emergency medical kits for use by all facility
healthcare personnel, and collect or receive expired, deteriorated, or recalled medications
for proper disposal. Thus, pharmacy systems that cover LTCFs must maintain a different
type and level o f inventory than retail pharmacy locations. Because o f the comprehensive
distribution system, and by virtue o f the quantities o f pharmaceuticals required by this
population, LTCFs are potentially an important source o f accumulated and unwanted
medication.
Driven by federal and state requirements and standards (Daughton, 2007), LTCFs
often dispose o f unwanted medications via sewage. There are presently a few studies
underway to examine and assess pollutant discharge o f these healthcare institutions.

69

especially from disposed pharmaceuticals. The US EPA Office o f Water 2008 Effluent

Guidelines Program (US EPA, 2008) aims to complete a health services industry survey
on the disposition o f unused pharmaceuticals in LTCFs, veterinarian offices, and
hospitals. In an effort to understand the extent o f discharge o f pharmaceuticals into water
and possible environmental effects, this study plans to request that these facilities submit
data on the quantities and types o f medications disposed, and the frequencies o f disposal
via the sink, toilet, or trash. Analysis o f this information could eventually be used to
inform a national standard for disposal and treatment o f unused pharmaceuticals at these
types o f facilities.
Prison Pharmacy Services
In an effort to service the greater than 2.2 million prisoners in federal, state, and local
incarceration facilities (US DOJ, 2005), prescription medications were the third largest
healthcare cost for prison institutions in 2002, behind hospital care and physician and
clinical services (DHHS, 1990). Pharmaceuticals for inmates are provided by either an
on-site pharmacy at the particular facility or an outside pharmaceutical company that
services correctional facilities. The private companies represent a “closed-loop” system
in which they do not offer retail pharmaceutical services to the public or non-incarcerated
individuals. This system is not different from the non-incarcerated public per se, but it is
important in the sense that it maintains its own inventory and distribution system.
In an audit o f the Federal Bureau o f Prisons Pharmacy Services (US DOJ, 2005),
I

prescription medication costs associated with waste were estimated at $2.81 million in
2004. This represented 2.54% o f the Bureau o f Prison’s total medication costs. Almost
half o f the cost associated with pharmaceutical waste was due to the transfer o f inmates.
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Transferred inmates are not required to take their medication with them to their new

facility. These medications are often abandoned in an inmate’s cell or locker. In addition,
upon transference, without regard to whether the inmate’s drugs have been sent along, an
inmate automatically receives an additional w eek’s supply o f each o f their prescribed
medications. The abandoned, unused drugs are disposed o f since they cannot be recycled
and dispensed to another inmate.
Another reason for discarded medications in the prison systems is from regular
searches o f an inmate’s belongings. Expired medications, and illicit drugs, are
confiscated during these searches and then disposed. In addition, a Bureau o f Prison’s
policy states that medications are only valid 90 days from date o f issue, regardless o f the
manufacturer’s expiration date. This results in more frequent and greater quantities than
normal o f drugs requiring disposal.
The categories o f medications taken by incarcerated populations are dominated by
anti-depressants. Research indicates that approximately one in seven prisoners in western
countries have psychotic illness or major depression and a greater number suffer from
more mild psychiatric illnesses, such as personality disorders (Fazel and Danesh, 2002).
In a 2006 Bureau o f Justice Statistics Special Report (US DOJ, 2006), it was estimated
that at midyear 2005, greater than half o f all inmates had a mental health problem,
defined as major depression, mania, or psychosis. This assessment represented 56% o f all
state prisoners, 45% o f all federal prisoners, and 64% o f all local jail inmates. The report
further indicates that 26.8% of state prisoners, 19.5% o f federal prisoners, and 14.8% of
local jail inmates were given prescription drugs to treat their mental illness. The
frequency o f prescribing o f these drugs rose 3% from 1997 to 2004. While the report
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does not specify which drags were prescribed, most likely the drags administered were
anti-depressants, anti-psychotics, and benzodiazepines.
Household Medicine Cabinets
That drags accumulate in the ubiquitous household medicine cabinet is common
knowledge. The medicine cabinet usually serves as the focal point for organizations and
agencies attempting to develop solutions for unwanted drag disposal. Obviously, the
ultimate reasons for why drags go unwanted and accumulate in the home are because
consumers choose or are told to not consume the medication, or forget they have them.
Why they choose to not consume the medications is varied and some reasons originate
from the healthcare practitioner, some from the patient, and yet still others from the
medication itself. As much as 60% o f all medication prescribed is taken incorrectly, or
not at all (NCPIE, 1995). This non-compliance includes behaviors such as forgetting to
take the medication, deliberate under-dosing, and hoarding medications to take later
(Figure 4). Medications that have the highest rate o f non-compliance include
gastrointestinal agents (84%), osteoporotic agents (82%), anti-arrhythmics (80%),
pulmonary agents (80%), and Alzheimer’s treatments (75%) (ScriptAssist, 2007).
Although the scope and magnitude o f drag stockpiling in the home are largely
unknown, coroner inventory data lend some insight as to the types and quantities that
occur (see Chapter 2 and Ruhoy and Daughton, 2007). One cause o f stockpiling is the
large numbers o f drags (including OTC medications) sometimes stockpiled by addicts
entering addiction recovery treatment (Lessenger and Feinberg 2008); these stocks must
all be disposed o f at once.
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An emerging indicator o f the significance o f household medicine accumulation as a
cause and source o f drug disposal is the increasing implementation o f unused-drug takeback events and programs in various states in the US. These take-backs are increasingly
popular as a local means to collect and dispose o f un-wanted drugs, taking the
responsibility out o f the hands o f the consumer. (In contrast to the US, many other
countries have had large-scale consumer drug “returns” programs in place for quite some
time; Daughton, 2003b).
At these local take-back events, organizers "will often attempt to record some sort of
measure o f the quantities o f medications that have been collected. Usually the measure is
simply the bulk -weight or volume o f the complete medications (often including the
packaging), providing little idea o f the associated quantities o f APIs. These bulk
measures might be useful in roughly comparing the success o f one take-back event to
another but they provide little data relevant to environmental issues. The types and
masses o f each API are the salient data. Take-back programs could be designed to assess
the categories and dosage amounts o f the APIs being returned, but this requires
substantial time, effort, and resources, as calculations must be made for every API in
each type o f medication (Ruhoy and Daughton, 2007). The work o f Braund et al. (2007)
is one o f the few examples o f detailed API-based cataloging that can be done at takebacks.
Regardless o f their limitations, take-back events serve to highlight the need for
prudent disposal o f accumulated household medications. Each take-back event invariably
collects numerous types of medications. For example, an event held in Sonoma County,
California during November 2007 collected 128 non-controlled human medications
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during a 2-hour local event. An event held on June 9, 2007 in the city o f Milwaukee
collected 2,387 pounds, including some packaging, o f non-controlled substances. This
event, which was done in conjunction with law enforcement and therefore could accept
the return of controlled substances, collected 985 controlled prescriptions. Group Health
pharmacies in Seattle collected 2 tons o f returned drugs from patients during
approximately a one-month period (Ervin, 2008). These events and others are
summarized by an Illinois-Indiana Sea Grant project (IISG, 2007). Many other
medication disposal programs are underway in communities across the nation.
Take-back events also reveal the difficulties in organizing collections at the local
level and perhaps the infeasibility o f collections becoming a standard, sustainable method
o f removal o f accumulated medications from households. Pharmacies are sometimes
reticent to participate; law enforcement must be present to allow for collection of
controlled substances; the public is encouraged to perhaps make trips that would
otherwise not be made; and hazardous waste handling are required for ultimate disposal
(via incineration or landfilling). These all impose monetary and labor costs and add to the
environmental footprint o f the overall process.
Perhaps more importantly, state governments are recognizing the need for guidance
and regulation and are discussing the establishment o f state product stewardship
programs. Several states, such as Washington (HB 2600:
http://wastenotwashington.org/HB2600summary.pdf), Maine (HB 411), Minnesota (HB
I

1959), and Iowa (IAS 579), have passed legislation that authorizes and guides some form
of a pharmaceutical collection and disposal project. Other states, while spécifie
legislation has not yet been enacted, have issued public guidelines and educational
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materials. An example o f such is the Guidelines for Proper Disposal o f Household
Medication issued by the New Jersey Department o f Environmental Protection
(http://www.state.ni.us/dep/dshw/rrtp/disposal.pdf).
Physician and Dental Offices
Beyond samples given to patients, physician and dental offices maintain particular
inventories o f pharmaceuticals on-site for intra-office procedures performed on patients.
There are many types o f procedures that can be done in the office or clinic setting, and
the type o f procedure performed depends on the medical or dental specialty o f the office.
The types of drugs needed for these procedures usually consist o f anesthetics, analgesics,
anti-pyretics, anti-microbials, steroidals, anti-inflammatories, immunosuppressives, and
cardiovascular (which are usually reserved for emergency scenarios).
Although over time a physician or dentist might develop a reliable assessment o f the
quantities and categories o f drugs that are necessary to have on-site so as to avoid having
excess, each office inevitably has some level o f expired drug or drug that is no longer
required that needs to be disposed. The method o f disposal historically has been
sewerage, office trash, hazardous waste, or sharps disposal.
Veterinarian Offices
As described for physician and dental offices, veterinarian offices also maintain an
onsite inventory o f drugs for intra-office procedures. There are, however, two main
differences. First, veterinary offices also serve as surgical centers for animals. So the
procedures performed are more invasive and intensive and therefore often require at least
greater quantities o f most o f the categories o f pharmaceuticals required for human
therapy (but often the APIs are unique and specific for veterinary use), as well as
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additional categories and higher potency drugs; veterinary offices also employ unique

categories, such as medications for euthanasia. Second, veterinarian offices usually
maintain their own pharmacies for filling outpatient prescriptions. So they face the same
problems as do human consumer pharmacies. Veterinary offices that practice animal
euthanasia can inadvertently dispose o f hazardous anesthetics by way o f improper
disposal o f carcasses, which can lead to acute poisonings o f raptors and other scavengers
(Daughton, 2007).
Cruise Ships
Cruise ships generate and discharge multiple types o f waste to the aquatic
environment, including sewage, graywater, hazardous wastes, oily bilge water, ballast
water, and solid waste (CRS, 2005). These wastes, if not properly treated and disposed
of, can be a source of aquatic contaminants with the potential to threaten human health
and damage aquatic life. While there are many other types o f shipping industries that
generate particular waste streams, with regard to public consumption and use o f
pharmaceuticals, cruise ships are the major source. A 2005 Congressional Research
Service (CRS) report on cruise ship pollution for Congress categorized pharmaceutical
waste from cruise ships as hazardous pollution (Copeland, 2005).
In 2000, a volunteer, independent science panel convened by the Ocean Conservation
and Tourism Alliance (OCTA) was asked to evaluate the management practices for cruise
ship wastewater discharges, and to recommend guidelines for good and improved
practices to the International Council of Cruise Lines (ICCL). Their report recognized
prescription and non-prescription drugs as a class o f water contaminants o f growing
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concern and recommended the Conned establish proeedures that are eongruent with the
US Environmental Protection Agency’s policies for waste disposal.
Waste generated from cruise liners has been recognized in the past. The ICCL set
forth 2001 industry waste management practices and procedures in the ICCL Standard E1-01 (Revision 3), revised in 2005 (Copeland, 2005). The Standard recognized that cruise
ships store and carry various pharmaceuticals, depending on the destination and
passenger population; they usually consist o f both prescribed and over-the-counter
medications. The document further describes particular handling methods: establishment
of a reverse distribution system for returning unexpired, unopened, non-narcotic drugs to
the issuing vendor, witnessed destruction o f narcotic drugs, obeying state waste
regulations for disposal o f unused drugs aboard the ship at time of docking, and onboard
incineration o f other non-narcotic drugs.
Currently, there are no accessible data regarding the quantities or categories o f the
pharmaceuticals commonly onboard cruise ships and to what extent they go unused and
are in need o f disposal or return. However, the nature o f the cruise line business is such
that it would not be unexpected that a large amount o f the drugs maintained onboard
would go unused since they are only present for health-care exigencies with passengers.
The onboard pharmacies are not intended to treat or manage chronic disease, but mainly
to support acute medical needs o f their passengers.
Abandoned Pharmaceuticals
Many of the sites and locations so far discussed may also be subject to the intentional
or unintentional abandonment o f pharmaceuticals by their intended user. For example,
vacationers may forget to repack their medications after their cruise experience, and
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children may bring their medicines to school and forget to return them home at the end o f

the day.
In addition, patients often have medications on their person when being admitted for a
hospital stay but hospital policies dictate that the patient must use the medication
administered by hospital pharmacy service and hospital personnel. This is to ensure
safety and proper treatment for the acute illness, as well as any chronic illness the patient
may suffer from. At the time o f discharge, a patient will often forget to retrieve their
medicinal belongings and effectively abandon these drugs at the hospital.
Perhaps more commonly are the drugs unintentionally left behind at various vacation
spots. While there is no reportable data on the subject, hotels, motels, and lodges
undoubtedly find and dispose o f medications left behind from vacationers
Armed Forces

'

The US Department o f Defense (DoD) maintains its own pharmaceutical supply and
distribution and its own process for return and disposal o f unused medications to support
and serve the military population. All DoD facilities, including the fleet, purchase
pharmaceuticals from the Defense Supply Center Philadelphia (DSCP) prime vendor
program. DSCP contracts with wholesalers to provide the drugs and delivery to the
customers.
Expired, unopened, and unused drugs are shipped to contractors specializing in the
recovery o f credits for unused or unopened expired drugs and subsequently use those
i

credits to replenish their stock. The military customers receive partial' credit for the return
of these drugs. Opened and unused drugs, on the other hand, are incinerated by licensed
contractors, who contract with DSCP. If the drugs are considered hazardous or controlled
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substances, the contractors are required to provide documentation of where and when the
destruction took place. Classes and doses o f the drugs are not documented. Because the
military maintains its own closed and organized system, sewerage and landfill disposal
apparently does not take place on a regular basis at military sites. While this system
seems to not significantly contribute to the problem o f the accumulation o f unwanted
medications, it is important to acknowledge the potential o f its contribution. There are
approximately 1.4 million active members o f the military (http://www.census.gov/PressRelease/www/2003/cb03 -ffD4se.html). If there were no effective system for removing
unused pharmaceuticals, the quantity o f unused drugs that would potentially accumulate
would be significant. It may be a helpful exercise to consider the implementation o f the
military system for unused medicine disposal in civilian sites as well. The ongoing
DoD/FDA Shelf Life Extension Program (SEEP) performs testing on various products to
effectively extend shelf life and thereby reduce the need for disposal
(https://slep.dmsbfda.army.mil/portal/page?_pageid=33,220I38&_dad=portal&_schema=
PORTAL).
Coroner Offices
Coroner offices were recently shown to perhaps be the only ready source o f data on
drug disposal in the US (see Chapter 2 and Ruhoy and Daughton, 2007). They also
represent a previously unrecognized source o f disposal themselves. In this work is
compiled a rich data set on the types, frequencies, and quantities o f APIs found by
medical investigators and then disposed into sewage. These data are particularly valuable
because they represent known input for individual APIs over a defined time frame to
particular sewage treatment plants (STPs). This allows calculations o f influent
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concentrations (averaged over time) for STPs. In Table 4, however, is presented some
summary data showing the therapeutic-class distribution o f nearly 400 distinct APIs that
had been disposed to several known STPs over a defined period o f time. This is the first
time that a sufficiently rich set o f data have been compiled to allow for meaningful
categorization o f data according to therapeutic class (according to the Anatomical
Therapeutic Chemical system: ATC). A major unknown and point o f debate is the extent
to which disposal of medicines contributes to the levels o f APIs detected in waterways,
which is a function o f the types and quantities o f medications disposed, the route of
disposal, the route o f administration (topically applied drugs can be efficiently washed
from the body and essentially serve as disposed drugs), type o f packaging, and the extent
to which any given API is metabolized (which dictates the relative contributions by
excretion). An even greater unknown is the relative contributions o f APIs among the
various types of locations from which they are disposed. In order to properly examine
this question, reliable and verifiable data are necessary for each o f these variables.
Historically, it has been difficult to determine what drugs, if any, were discarded into the
toilet or trash, and in what absolute and relative quantities. The lack o f information is
mainly due to the absence o f any reporting system. Historically, the advice from
healthcare personnel and pharmacists has been to simply discard unwanted medications
via the sewer or the garbage. This practice took place consistently and persistently
without any perceived need to report or file information regarding the details o f this
behavior.
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Conclusions

A frequent criticism o f focusing on drug disposal as a source contributing to APIs in
the environment is the lack of understanding o f its overall significance — which is
believed by many to be inconsequential. This is primarily a result o f the absence o f data
regarding the types and quantities o f APIs that are actually disposed during defined
periods o f time, coupled with a lack o f appreciation for the many sources that contribute
to disposed drugs. This data gap was the primary driver behind Chapter 2 which uses
coroner inventory data to collect real-world disposal data from known segments o f the
population (see also Ruhoy and Daughton, 2007).
Regardless o f what fraction o f individual or total APIs in the environment originate
from disposal o f unused drugs, it is important to note that it is not just the quantities of
APIs introduced to the environment that would be important with regard to their potential
environmental impact. Also o f importance, but rarely mentioned, would be any temporal
or spatial characteristics of their release that differs from the continual but low-level
releases resulting from intended use by the general population. Disposal holds the
potential to introduce transiently high quantities o f APIs into sewage (Daughton and
Ruhoy, accepted 2008).These spikes in concentrations could lead to increased exposure
for aquatic organisms, for example, should the APIs survive sewage treatment; it may be
likely that risks could also be increased with respect to the homeostasis o f the unique
assemblages of microbial consortia that exist at each activated sludge sewage treatment
facility.
There are several aspects unique to the purposeful disposal o f drugs by flushing
compared with the unintentional release (via excretion and bathing) o f APIs resulting
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from their designed therapeutic usage that could prove significant with respect to
environmental exposure. These aspects serve as additional imperatives for ensuring that
the disposal o f drugs is environmentally sound.
The factors controlling drug wastage and leading to disposal are numerous, varied,
widespread, and complex. Although this analysis could be used to ensure that the design
o f programs for collecting leftover drugs is better informed, approaches for leftover drug
control such as local take-backs or other types o f local “collections” may not succeed in
efficiently capturing stored medications in a timely manner (to reduce accidental
poisonings). These programs also have significant sustained costs. A preferred approach
would prevent the accumulation (and need to dispose) o f medications to begin with - an
up-stream “green” approach to preventing pollution as opposed to a “down-stream”
approach directed at controlling pollution. An effective and efficient approach aimed at
pollution prevention would obviate the need for drug collection programs. O f
significance is that a holistic pollution prevention approach could also potentially afford a
number o f advantages for healthcare, including improved therapeutic outcomes, reduced
healthcare expenses, and lower incidence o f drug diversion (which facilitates abuse and
poisonings o f humans and animals). The accumulation of medications is a rare instance
where human health and safety is linked directly with environmental integrity. These
ideas are embodied in what is termed pharmEcovigilance (Daughton and Ruhoy, 2008).
Take-back events, however, do have the potential to contribute substantial data
i

relevant to the general population. Take-backs can be held in just about any geographic
area under the appropriate circumstances. They can also be held indefinitely, for as long
as the organizers are able and willing to participate. These events have the distinct
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advantage o f surveying the consumer and inquiring as to why the medicine accumulated
as well as other parameters regarding the history o f the use and non-use o f the
medication. These drugs can be categorized and counted, and the information can be
compiled in a database. As mentioned earlier, these events usually simply record the
weight o f the entire collected medication, which often includes packaging. While weight
can be useful to compare one take-back to another, it does not provide information
regarding the constituent APIs. Another major limitation o f data collected from takebacks is that it does not necessarily represent the frequency or rate at which drugs would
be disposed on a sustained basis (because consumers often stockpile their medications
over long periods of time for one-time disposal at take-back events). Considering the
importance o f this information, a standardized methodology for collecting data from takeback events or returns programs would be useful to environmental scientists, to the
healthcare and insurance industries, and to regulators. For future studies, a
recommendation would be that data for APIs from collected drugs be coded according to
therapeutic class (e.g., using the Anatomical Therapeutic Chemical [ATC] system:
http://www.fmrc.org.au/atc/index.htm), which would greatly facilitate the sharing and
intercomparison o f data.
By categorizing the coroner drug-disposal data collected by Ruhoy and Daughton
(2007, unpublished) using the ATC system, it becomes immediately clear that the bulk of
the API mass disposed (>94%) represented only five o f the 14 ATC therapeutic
categories: Alimentary Tract, Nervous System, Cardiovascular System, Anti-infectives,
and Musculoskeletal System (Table 2). The other nine categories therefore were
negligible contributors to the total mass o f APIs introduced to the environment by the
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coroner; considerations o f potency would need to be evaluated, however, to eliminate
these categories as contributors to overall hazard in the aquatic environment.
The major opportunities for pollution prevention are discussed. These opportunities
are based on minimizing the types and quantities o f drugs dispensed to consumers (or
how they are made available OTC) as well as altering the consumption and behaviour
patterns o f consumers. Unit dispensing, as opposed to bulk dispensing, has the potential
to deliver the correct dosage o f drug at the correct timing. Already in widespread use in
healthcare institutions, such as hospitals and LTCFs, unit dosing not only has the
potential to reduce the inventory o f medications in a patient’s possession, but can also
reduce medication errors - whether it is the amount or time o f consumption. To perfect a
method o f unit dosing in the retail market may be a perceived obstacle, but technologies
already exist regarding unit dose re-packaging (e.g., see: Parata Systems:
http://www.parata.com/adhere/index.php) suitable for use in doctor offices and
pharmacies. At a minimum, low-quantity prescriptions coupled, if needed, with more
frequent refills could be encouraged when the need for an ongoing course o f treatment is
not clear, especially when longer-term (e.g., 90-day) prescriptions are being considered.
Trial prescription periods and increased monitoring o f patients can only have the
benefit o f improved health outcomes, improved physician-patient relationships, and a
reduction in the quantities o f unused, unwanted, ineffective, and expired medications.
Identifying poor compliance and reasons for lack o f adherence will help healthcare
personnel to adjust treatment or to better counsel the patient accordingly. In addition,
identifying good compliance can serve to allow the healthcare team to assess
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effectiveness o f treatment and adjust as necessary. These steps will assist in reducing the
accumulation and eventual disposal o f unused medications.
The information and evaluation provided here could be used to design the framework
for a holistic pollution prevention program for medications. Such a program would serve
an integral role in pharmEcovigilance as conceptualized by Daughton and Ruhoy (2008).
Designing an effective program will also afford the unusual opportunity for
collaborations among professionals from the healthcare and environmental science
communities, which could yield various unanticipated beneficial outcomes.
Numerous factors play roles in the accumulation o f drugs by end-users, whether they
are healthcare professionals, physicians, patients themselves, veterinarians, farmers, or
humanitarian relief workers. Expiration o f prescribed drugs is a reason for accumulated
drugs, but numerous other factors play significant roles, including patient non-adherence
and over-prescribing or excessive purchase; these have been summarized by Daughton
and Ruhoy (2008). Poor adherence and non-compliance continues to be a major public
health concern (NCPIE, 2007). Significantly, the number o f consumers who do not
follow medication regimens in the US continues to be substantial, and addressing the
causes could improve therapeutic outcomes and reduce morbidity and mortality.
Patients will imprudently discontinue medications for a wide variety o f reasons,
including adverse effects, the perceived absence o f beneficial effects, inconvenience in
dosing schedules, change in therapy as prescribed by their physician, or even a poor
perception of the severity of their illness. See Pound et al. (2008) for an in-depth
discussion o f compliance.
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Sites where wasted drugs accumulate extend well beyond the household medicine
cabinet. Some drugs are simply forgotten by consumers at a distant location (i.e., hotels,
workplace, and hospitals), some are lost track o f (e.g., when stored in obscure, alternative
places to secure them from others), and some are intentionally abandoned. Physician,
dental, and veterinary offices have supplies o f drugs on hand for intra-office procedures
and sample dispensing. However, some areas o f substantial drug wastage are independent
o f the individual consumer as a patient. These locations are associated with the demands
and expectations o f the public for the easy accessibility and availability o f medications
should they be needed. Public buildings, vacations areas and maritime vessels, and
societal institutions such as prison systems and military bases are all locations where
drugs are stored in large quantities in case the need arises. This ready-as-needed approach
maximizes the chances that the medication will not be needed, eventually leading to
expiration and the necessity for their disposal.
The flow chart in Figure 3 represents an overview o f the various locations where drug
buildup and eventual disposal may prove to be significant. It begins with the actual
production o f the pharmaceutical and traces the many places in which’a drug may end up
following its purchase, either by prescription, OTC, importation from a foreign country,
illegal web-based pharmacy, or by other means.
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ATC
Code

Quantity (mg)
disposed

ATC Main Group

#of
APIs

% of Total

A

Alimentary Tract

18,685,27

56

34.6

N

Nervous System

16,510,96

95

30.6

C

Cardiovascular System

6,331,976

71

11.7

J

Anti-infectives

5,608,735

45

10.4

M

Musculoskeletal System

3, 851,949

21

7.1

R

Respiratory System

984,780

16

1.8

B

Blood

721,450

9

1.3

V

Various

622,800

1

1.2

P

Antiparasitics

236,269

2

0.44

L

Antineoplastics

186,013

14

0.34

G

GenitoUrinary/Sex Hormones

146,440

23

0.27

H

Hormonal Preparations

50,601

10

0.09

S

Sensory Organs

4,375

1

0.008

D

Dermatologicals

3,420

3

0.006

53,945,04

TOTAL

367

Table 2: Summary of API Masses Disposed to Sewerage by a Coroner Office during
a 12-Month Period^: Categorized by Therapeutic Class^
^Data acquired January-December 2005 from Las Vegas, NV, with a resident
population o f approximately 1.8 million, and annual visitors o f over 38 million.

Given the thousands o f APIs in commercial use for treating a wide spectrum of
conditions in both humans and animals, it is critical to have a framework that organizes
this expanse of potential environmental chemical stressors in a standardized way that
enhances communication and exchange o f data among scientists and also the healthcare
communities. There are two systems in wide use for categorizing drugs, primarily for the
continual studies that surround drug utilization. One o f these, adopted for the study here,
is the Anatomical Therapeutic Chemical (ATC) system
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(http://www.fmrc.org.au/atc/index.htm), which is most commonly used outside the US

but has the advantage in that it uses a more detailed hierarchical system that allows better
distinguishing between closely related drugs. The ATC system parses all drugs into 14
different major groups (excluding an “other” category) according to the primary organ or
physiological system for which they are prescribed; more detailed, lower levels in the
hierarchy classify according to their chemical or pharmacological properties (such as
mode or mechanism of action). An analogous system (ATCvet) is in place for veterinary
drugs. The ATC system is maintained by the WHO Collaborating Centre for Drug
Statistics Methodology. Every medication is classified according to its primary
therapeutic use - classifications composing 14 primary anatomical groups (including the
category ‘various’ and an additional 15th category for veterinary drugs), followed by
succeeding detailed subgroups. Every API is listed by only one name - the International
Nonproprietary Name (INN), which is the official non-proprietary or generic name
assigned by WHO to each API (http://www.who.int/medicines/services/inn/en/). An
analogous classification system (ATCvet system: http://www.whocc.no/atcvet/database/)
is in place for classification o f veterinary medicines. For most APIs, the ATC code is
used to classify a veterinary product; in these instances, the ATCvet codes are created
simply by placing the letter Q in front o f the ATC code; new ATCvet codes are created
only for veterinary products whose indications cannot be mapped onto analogous human
APIs.

UNIT DOSING
Minimizes the quantity dispensed. The evidence that it improves patient adherence
(and therapeutic outcomes), by ensuring that it will be consumed (and that wastage
thereby minimized), may be at best marginal (Larsen and Haugbolle, 2007) but still
equivocal (Connor et al., 2004); this is an important area for further investigation to
further elucidate its potential benefits.
Ensures proper dosing for optimal healthcare outcome. Automated unit dose ondemand dispensers have been expensive and only suited to healthcare within facilities.
But new technologies are becoming available; as one example, see; Parata Systems:
http://www.parata.com/adhere/index.php
TRIAL SCRIPTS
Allow for management o f ineffective treatment, adverse effects, or poor compliance.
Necessary before prescribing multi-month supplies.
LOW QUANTITY PACKAGING OF OTC MEDICATIONS
Lessens chance o f expiration. Allows consumer to experiment before deciding whether
a larger quantity is warranted.
INCREASED MONITORING OF PATIENT
Im prove patient care and health status b y a ssessin g effects o f treatm ent on both d isease
and p atien t’s d isp osition . H elp s to id en tify com p lian ce issu es early in treatment.
IM PL E M E N T P R A C T IC E OF C O N C O R D A N C E

The concept o f concordance was developed in the UK. Its thrust is to actively involve
the patient in the treatment process, developing mutual trust with the intent of
improving compliance (Pound et al. 2005); actions include selecting medication and
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dose to minimize side effects (and clearly explaining potential side effects and what to
do to reduce their occurrence); minimizing numbers o f medications; simplifying
dosage regimens; allowing patient to make adjustments to therapeutic regimens (e.g.,
self-regulation). Indeed, involving the patient seems to be a major avenue toward
improving patient compliance (van Dulmen et al., 2008). Interaction with the patient
(especially when multiple physicians are involved) is one o f the only ways to
understand the extent o f polypharmacy, a concern that continues to grow (Gorard,
2om%.
FREE SAMPLES AND DONATIONS
Types and quantities maintained at healthcare facilities can be carefully evaluated for
need prior to acceptance. Assess the patient’s dedication to actually using the samples
before providing them. Note that physician samples can be donated to charitable
institutions by licensed practitioners if the samples meet certain criteria (e.g., expiry,
packaging) set forth in CFR Title 21 (CFR 200). The barriers to donation o f leftover
drugs by consumers are covered by McKee (2006). Various state legislation pertinent
to drug reuse has been proposed or passed since 2006 (NCSL, 2008).
REDUCE INCENTIVES FOR EXCESSIVE PURCHASING
Implement procedures that would encourage insurance companies and pharmacies to
re-evaluate procedures for dispensing large quantities o f medication that later are never
used. Better control automatic refills, especially for the deceased.
able 3; Major Opportunities for Preventing the Wastage and Accumulation of
Medications

90

EPISODIC RELEASE

Release by disposal from just one or a few individuals might result in brief, episodic,
transient spikes in concentrations o f APIs in sewage - significantly higher than the
more constant “ambient” levels resulting from the more continual, low-level release of
APIs via excretion from numerous individuals living in communities served by the
same sewage treatment plant.

TYPE OF API

The types and quantities o f APIs released by disposal will favor certain drugs
compared with their release by excretion/bathing. One example is those drugs subject
to abuse and which are recommended to be disposed via flushing. Another example is
those medications that have universally poor compliance rates (e.g., anti-depressants).

BYPASSING ADME

Disposal by flushing o f those APIs that would otherwise undergo extensive
metabolism before excretion could be a significant source for these particular APIs in
the environment. The disposal o f one dose of carbamazepine (CBZ), for example,
could contribute the mass o f CBZ in the environment comparable to what would result
from roughly 29-87 ingested doses (calculated from data in Ruhoy and Daughton
2007; see Chapter 2).
TIMING OF DISPOSAL
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The times o f drug disposal can be “compressed” compared with those for
excretion/bathing. Certain locations (such as LTCFs) often dispose o f drugs en mass
on particular days or times o f day after certain quantities have accumulated. A
confluence o f similar facilities (such as LTCFs) that practice routine drug disposal and which the same STP serves - could amplify episodic releases. The season o f the
year could also make disposal more significant when those medications that tend to be
taken during certain seasons are disposed during seasons when their usage is lowest.
LOCATION OF DISPOSAL

Certain drugs are used disproportionately at certain locations (e.g., antipsychotics at
LTCFs). A confluence o f similar facilities (such as LTCFs) that routinely practice drug
disposal and which are served by the same STP could amplify episodic releases.
Table 4: Unique Aspeets o f Drug Disposal via Flushing (in Contrast with
Exeretion/Bathing) that Could Prove Environmentally Significant
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CHAPTER 4

MANAGING UNUSED PHARMACEUTICALS A RISK MANAGEMENT PERSPECTIVE
Overview
The fate o f unused pharmaceuticals is poorly understood, although the issue has
received increasing attention over the past several years. As argues in chapters 2 and 3,
households are a critical point at which substantial quantities o f a variety o f
pharmaceuticals accumulate. These accumulated pharmaceuticals are susceptible to
undesirable exposures, including accidental misuse, intentional misuse/abuse,
unauthorized transfer to a third party (e.g. dropping off controlled substances at a
pharmacy or sharing with a family member or friend), and environmental exposure
through illegal dumping or disposal to municipal sewers or landfills. Reducing the
transfer o f pharmaceuticals from households to inappropriate locations requires an
understanding of the factors that promote or minimize acquisition, accumulation, and
inappropriate use or disposal. Certainly, the efforts to reduce accumulation and
inappropriate transfer may influence alternative behaviors. Potential undesirable
outcomes include inadequate medication, a transfer o f unused pharmaceuticals from one
inappropriate disposal to another, and illegal disposal behavior. However, with proper
monitoring these unfavorable behaviors may be mitigated or avoided.
Chapter two presented some novel data on the contributions and types of
pharmaceuticals that accumulate at households, based on data from the Clark County

100

(Nevada) Coroner’s Office (see also Ruhoy and Daughton, 2007). Chapter three

cataloged the reasons for, and locations of, accumulation of pharmaceuticals in the US,
and evaluated the role o f a pollution prevention approach to reducing those
accumulations (see also Ruhoy and Daughton, 2008). This chapter takes a risk
management approach to further develop the pollution prevention strategy used in
chapter three for the case o f household accumulation o f pharmaceuticals.
The risk management perspective is particular helpful in addressing tradeoffs. Risk
management, which is practiced by everyone from insurance agencies to the Department
of Homeland Security, distinguishes between the likelihood that things— good or bad—
will happen, and the extent of the consequences o f those good or bad things (see
Kammen and Hassenzahl, 1999; Hassenzahl and Finkel, 2008). For example, it is true
that if all the landfills in the US were flooded at the same time, a massive environmental
release o f pharmaceuticals would ensue. But this is so extremely improbable that it is not
a scenario worth considering. The risk perspective can be used to frame possibilities, and
as one-way to help distinguish among different and effective management strategies.
Central to this approach is to understand the likelihoods o f various behaviors, practices,
and impacts, and the consequences, whether harmful or beneficial, associated with those
behaviors, practices and impacts.
Outlined here are the key drivers o f household accumulation of unwanted
pharmaceuticals, strategies for reducing such accumulation, and potential unintended
consequences of changes to those drivers. Reducing undesirable exposures can best be
accomplished through a strategy that integrates improved prescribing practices,
information for consumers about prescription compliance and appropriate disposal.
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clarification o f legal disposal options, and changes to chain o f custody that allows and
regulates return o f unused pharmaceuticals to points of purchase. Implementing this
strategy would require cooperation among a range o f agencies, including the Department
o f Justice, the Food and Drug Administration, the Environmental Protection Agency, and
the Centers for Disease Control.

Introduction
That pharmaceuticals and their active ingredients exist in our environment,
particularly our waterways, is now undisputed. The interpretation o f their existence,
however, with regard to risk o f detrimental effects on human and ecological health, is
poorly understood. Examined and assessed here is the transfer o f pharmaceuticals from
intended and appropriate locations to unintended and inappropriate locations. Prospective
options for reducing those transfers and the potential impacts of those transfers are
explored. Finally, opportunities for additional research on accumulation and transfers that
would most likely reduce future needs for disposal are proposed.
The presence o f pharmaceuticals in the environment is the focus o f an ongoing dialog
among private industries, the public, and governmental agencies. The US market
accounts for 47.7% o f global pharmaceutical sales (IMS, 2006). This lion’s share o f drug
use has not been without consequence. Concentrations o f active pharmaceutical
ingredients (APIs) have been detected in multiple water systems throughout the country
i

(Daughton, 2001; Kolpin, et al. 2002; Fent et al., 2006) and have been the subject of
recent local, national, and global media headlines. Researchers in a variety o f fields
continue to assess, analyze, and decipher the extent to which these compounds exist, and
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why they exist, in the nation’s water. Law and policymakers (Crow, 2008) are anxious to
understand the issue and enact regulations that would serve to not only protect the public
but address public fears (i.e., SB 966, 2007; MA 2182; HB 3064, 2008). In April 2007,
the US Senate held a hearing to review federal efforts to assess and regulate drinking
water contaminants, specifically pharmaceuticals (Argent & Schuster, 2008).
Primary treatment o f disease and illness with the use o f pharmaceutical medication
has increased steadily over the past few decades. A 2007 study by Medco Health
Solutions, Inc. demonstrated 51% o f American children and adults were taking one or
more prescription drugs to treat a disease diagnosed as chronic, or long-term. Since this
does not correspond to a similar increase in the diagnosis o f chronic conditions (Medco
Health Solution, 2008), by implication, physicians increasingly turn to pharmaceuticals to
treat and manage ailments. This increase in drug consumption would be expected to
parallel an increase in the presence o f pharmaceutical residues in our water.
The presence o f APIs in the environment results from two major sources: excretion
(and bathing) and disposal. The extent to which each contributes to the relative
concentrations detected in water systems is unknown and difficult to assess (see Chapter
2 and Ruhoy and Daughton, 2007). Excretion o f any particular medication depends on
that drug’s pharmacokinetic profile, as some drugs are extensively metabolized, some are
metabolites or biotransformation byproducts that may have biological activity similar to
the parent API. The metabolic and physiologic profile of the consumer is another
important factor in the subsequent excretion o f the consumed drug. In most cases, proper
consumption and natural excretion of a required medication are desired for beneficial
therapeutic outcomes. However, optimal prescribing patterns and patient compliance may
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reduce the quantity o f medications that remain unused (see Chapter 3 and Ruhoy and

Daughton, 2008). They may as well reduce the level of consumption o f medications and,
by extension, the quantity o f compounds excreted. Regardless, discarding pills directly
into sewage systems releases a much higher concentration of drugs into the environment
than does excretion (Reid, 2007).
Disposal and removal of unwanted drugs can occur through household wastewater
(toilet and sink), landfill sites (trash), or diversion practices, sometimes referred to as
“pharming”. These three pathways for unwanted drugs are inappropriate transfers.
Another major route - disposal (or amendment) o f biosolids on agricultural land, as is
currently the accepted standard method is another potential inappropriate transfer.
Pharmaceutical residues have been measured in landfill leachate and therefore have the
potential of entering the wastewater systems as well (if the leachate is transferred). The
frequency and quantity o f drugs that are discarded through either system in the US is an
open question and an area o f much needed research.
The predominant method o f disposal o f unwanted pharmaceuticals, based on small
surveys both in the US and England, is via household waste and primarily in the trash
(Bound and Voulvoulis, 2005; Kuspis and Krenzelok, 1996). Chapter 2 explored the
quantities and categories o f drugs discarded, mostly by flushing, by a local coroner
office. The study demonstrated greater than 102,000,000 mg (102 kg) of various APIs
disposed in a thirteen-month period for a population o f approximately 2 million. To
further elucidate the extent to which unused pharmaceuticals are discarded, the USEPA’s
Healthcare Industry Survey is a current project designed to characterize medication
accumulation and disposal in long-term care facilities (US EPA, 2008).

104

The safest method of disposal for unused pharmaceuticals remains unclear. The desire
to prevent drug residues in the environment can often be in conflict with the inherent
need to protect public health. Wasted pharmaceuticals that remain in households or other
potential areas o f accumulation (see Chapter 3 and Ruhoy and Daughton, 2008) are
readily available to those who seek to misuse, divert, or abuse these medications.
Prescription drug diversion and the non-medical use o f these medications is a current
public health and safety concern (Inciardi et al., 2007; Lessenger and Feinberg, 2008).
Rates o f abuse o f prescription and over-the-counter medications (OTC) among
teenagers are very high. Use o f hydrocodone, for example, by teens for non-medical
purposes has been reported for almost 10% o f 12‘*' graders (Keuhn, 2007) in the US.
These drugs are also accessible for the potential o f accidental poisonings. Deaths due to
overdoses were reported in significant frequency in death certificate data (Wysowski,
2007). Deaths from medication mistakes at home increased from 1,132 deaths in 1983 to
12,426 in 2004 (Johnson, 2008). This concern fostered the 2007 federal guidelines for
disposal o f unwanted medication. These guidelines recommend the disposal o f drugs into
the trash, after first adulterating them, although the APIs remain in their original chemical
state, and sealing them in a container. A list o f drugs with a greater propensity for
diversion was included with the recommendation for toilet disposal (ONDCP, 2007).
The risk to human morbidity and mortality from exposure to environmental
concentrations is an area o f active investigation and conversation. Kidd et al (2007)
demonstrate that aquatic flora and fauna are susceptible to, and possibly adversely
affected by, pharmaceutical contaminants. Medicines designed for human use may induce
physiological and pathophysiological effects in aquatic organisms since receptor proteins
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are shared among species, (3-adrenergic receptors, for example (Owen et al., 2007).
Detrimental effects on wildlife o f drugs at concentrations lower than 0.1 ng/1 has been
demonstrates (D ’Ascenzo et al., 2003; Warner and Jenkins, 2007; Boxall, 2004). Human
exposure to pharmaceuticals through environmental exposures is difficult to assess.
Human exposure to therapeutic doses is obviously not the concern. Aquatic exposure
rates are at least 100 fold lower than those required to produce minimal therapeutic
effects in humans (Kostich and Lazorchak, 2008) and environmental and human health
risk assessments seemingly demonstrate no appreciable immediate adverse effects to
aquatic environments (Winter MJ et al., 2007) and humans (Schulman et al., 2002;
Schwab et al., 2005; Daughton, in-press) from exposure to low concentrations.
However, chronic, low-level, involuntary exposures to multitudes o f APIs may pose a
potential risk to human health (Collier, 2007; Daughton, in-press), particularly to
vulnerable populations (Filby et al., 2007), such as neonates (Grandjean et al., 2007).
Pharmaceuticals are designed to be biologically active at very low concentrations and are
approved to treat a specified pathology, not the population at large. In addition, various
drug-drug interactions are well established in the human body and these interactions may
play a role in effects due to environmental exposures to pharmaceuticals as well.
Bioaccumulation and bioconcentration has yet to be quantified and may also result
exposure levels substantially greater than those measured in the environment (USGS,
2008).
i

Some APIs, or combinations o f APIs, may present greater toxic concern than others.
Sanderson et al. (2004) established a predicted rank order o f relative toxicity o f four
classes o f pharmaceuticals, while noting that all examined pharmaceuticals have possible
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toxicity. In rank order (from most to least toxic) they are: sex hormones, cardiovascular

agents, antibiotics, and anti-neoplastics. Some drugs demonstrate considerable mixture
toxicity, such as additivity or synergy, in combinations with other drugs o f the same class
(Cleuvers, 2004), or o f different classes (DeLange et al., 2006). Kostich and Lazorchak
(2008) found mutagenic cytotoxic agents display cumulative toxicity and long-term
effects that appear linearly related to dose. Mixtures of drug compounds at environmental
levels were found to inhibit growth o f human embryonic kidney cells (Thrall, 2006).
These are important and relevant findings since APIs rarely appear in the environment as
single agents (Focazio et al., 2008).

Discussion
A four-stage risk management approach
Risk management can be an effective way to deal with complex environmental
problems. The following paragraphs introduce a 4-stage risk management approach,
which is then applied to the management o f household pharmaceuticals.
A risk management approach takes a broad perspective on exposures to, and effects
of, a particular hazard. Morgan (1981) describes four alternatives for risk management:
(1) alter the built or human environment; (2) avoid or modify exposure processes; (3)
avoid or modify effects processes; and, (4) mitigate or compensate for effects.
Understanding the process by which the risk takes place can effect minimizing the
potential risk.
In the case o f household accumulation o f pharmaceuticals, the hazard analog is the
transfer of unused pharmaceuticals from appropriate to inappropriate locations. An
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“appropriate” location for pharmaceuticals refers to any location for which

pharmaceuticals are intended and originally conceptualized, or safe and legal disposal
endpoints for those that go unused. These locations include manufacturing and
distributing centers, pharmaeies, sites intended for use in case o f need by different
segments o f the populations (Ruhoy and Daughton, 2008), and the consumer household
prior to its directed and expected consumption.
“Appropriateness” also includes a quantitative dimension. So while it is appropriate
to have pharmaceuticals present in pharmacies and perhaps in physician offices, it is also
important that the amounts of the drugs residing in these otherwise appropriate locations
would be the minimal amount required to fulfill their intended roles - in other words,
their “appropriate” roles.
"Inappropriate" locations, therefore, refers to those locations where pharmaceuticals
reside without the apparent objective o f intended use and consumption. In some cases,
these locations may be similar to the locations deemed “appropriate” (indeed, a single
location may simultaneously be appropriate for some pharmaceuticals yet inappropriate
for others). Once drugs become unwanted or unusable, either due to expiry, intolerable
effects, or patient non-compliance, they are considered pharmaceutical waste and their
residence beeomes an inappropriate location. In addition, excessive production and stock
o f otherwise “appropriate” locations, such as distribution centers, pharmacies, physician
offices, and pharmaceutical representative inventory results in the presence o f drugs in an
“inappropriate” location since their supply is not met by patient demand. Finally,
“inappropriate” locations would almost obviously include any site that may possess
medications in an illegal, immoral, or unethical manner.
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From the risk management perspective, dealing with unused pharmaceuticals can be
conceptualized in four stages: (1) alter the ways in which pharmaceuticals arrive at
accumulation location; (2) avoid or modify the extent to which pharmaceuticals that
arrive are allowed to accumulate; (3) avoid or modify the extent to which accumulated
pharmaceuticals are transferred from appropriate to inappropriate locations (or between
inappropriate locations); (4) mitigate or compensate for the effects o f unused
pharmaceuticals once transferred to inappropriate locations. This discussion focuses
mainly on the household medicine cabinet with some ancillary discussion points
regarding other locations. “Medicine cabinet” here is a catchall phrase; medicines are
stored in a range o f locations within a household, and often in multiple locations within a
single household.
Pharmaceuticals are designed to treat human maladies and their deliberate context is
to be prescribed for a patient in order to alleviate symptoms, improve quality o f live,
enhance lifestyle, ameliorate disease, or prolong life. Once pharmaceuticals are unused
and unwanted they are then technically in an inappropriate location even though it is
possible they were originally appropriately located. This inappropriate location may place
the public in danger as these drugs may be accessible and available for intentional misuse
and abuse or for unintentional usage, including dermal and pulmonary exposure, as well
as ingestion. From this inappropriate location, these drugs are inappropriately transferred
to another inappropriate location, with potentially greater adverse environmental impact.
For example, an unwanted drug may be transferred from the household, which exposes a
limited number o f people to its accumulation, to an area o f broader exposure potential,
such as natural systems.
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Wasted dmgs are disposed o f either via household trash, toilet, sink; through
accidental ingestion; or by intended diversion, that is, the inappropriate transfer to
another for whom the medication was not prescribed. In the case o f controlled
substances, this final scenario would violate the Controlled Substance Act (CSA)
enforced by the US Drug Enforcement Administration (DBA) that prohibits the transfer
of all controlled medication beyond the prescribee, even a physician or a pharmacist. In
addition, the diversion o f these substances contributes to dmg addiction, as these dmgs
are often re-sold to those who seek to misuse these prescription dmgs. Even in the case of
non-controlled substances, transference would violate FDA mandates (US FDA, 1988)
and place untold number of consumers in danger as all medication has the potential to
cause toxic reactions under certain circumstances.
In many locations, medications disposed into the toilet enter the seWerage systems.
From there they are treated in the sewage treatment plant (STP) and eventually result in
treated sludge dispersed on fields, treated sewage released into the aquatic environment,
or treated sewage injected into the ground. It is important to note that raw sewage is also
frequently released - on purpose and by accident. Therefore, the pharmaceuticals
entrained in such sewage have the potential to result in exposures to both terrestrial and
aquatic organisms. Indeed, reproductive, endocrine, development, and behavioral effects
on aquatic organisms have been reported.
Medications disposed into the household trash are collected by municipal waste
I
handlers and are eventually (if not diverted by pharming or wildlife) disposed in landfill
systems or incinerated. While not directly injected into wastewater, these pharmaceuticals
have the potential for long-term persistence and eventual transport into ground water.
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Pharmaceutical compounds have been detected in leachate samples from municipal

landfills (Barnes et al. 2004). Lee and Jones-Lee (1998) suggest that older landfills with
liners have poor groundwater monitoring systems and are unreliable. The latest
geoengineered landfills collect the leachate and either treats it on-site or it is transported
to an STP. Either way, treated effluent is often discharged into receiving streams.
Pharmaceuticals that remain in the household are available for accidental ingestion
and potential subsequent poisoning. Unintentional pharmaceutical poisonings o f children
results in tragic and unnecessary morbidity and mortality each year. In 2005, according to
the American Association o f Poison Control Centers (AAPCC), o f the almost 2,500,000
human exposures reported, 64.5% were reported to be children under the age o f 20 years
and 50.9% under the age o f 6. This group o f children and adolescents also accounted for
9% o f the 1,261 fatalities due to poison exposure. The majority o f these pediatric and
adolescent fatalities were the result o f intentional exposures - suicide, misuse, and abuse
- to drugs. O f the reported deaths in children younger than six years o f age, 16 were
known to be unintentional. O f the 14 medication-associated deaths, 13 were from
exposures to prescription medication, 5 o f which contained opioids.
Finally, pharmaceuticals that are allowed to accumulate in inappropriate locations are
accessible to those who seek to misuse, divert, or abuse these drugs. According to the
National Center on Addiction and Substance Abuse at Columbia University (CASA),
between 1992 and 2003, while the US population increased 13% and the number o f
prescriptions written for non-controlled drugs increased 57%, the number o f prescriptions
filled for controlled drugs increased 154%. During the same period, there was a 90%
increase in the number o f people who admitted abusing controlled prescription drugs.
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Alarmingly, there was a 203% inerease among 12- to 17-year olds (212% by 2003) and a
78% increase among those greater than 18-years old (81% by 2003).

CASA reports that the 15.1 million Amerieans abusing eontrolled preseription drugs
exeeed the eombined number abusing eoeaine (5.9 million), hallueinogens (4.0 million),
inhalants (2.1 million), and heroin (.3 million). The use o f alprazolam, oxyeodone, and
methylphenidate by teens (ages 1 2 - 1 7 ) inereased 212% between 1992 and 2003. In
2003, 15% of teens abused or were addieted to eontrolled drugs, with opioids, CNS
depressants, and stimulants being the most frequently reported.
Aeeording to the Drug Abuse Warning Network (DAWN), in 2005 there were almost
600,000 visits to US hospital emergeney departments due to non-medieal use of
pharmaeeutieals (e.g., reereational or unintentional use). This represents a greater than
20% inerease from 2004. Bentur et al. (2004) found 84% o f deliberate self-poisonings in
the study population involved pharmaeeutieals.
The following paragraphs develop the key factors that determine the impact or
importance o f eaeh o f the four risk management stages for the ease o f household
aeeumulation, as operationalized for the ease o f household pharmaeeutieals. For eaeh
stage, some key faetors, and their implieations, are outlined in Table 7. The hazard in this
ease is defined as transfer from appropriate loeation to inappropriate loeation. For eaeh o f
the four risk management stages, understanding the faetors that determine whether that
stage is more or less likely to inerease impaets is worthwhile. A detailed eomparison
aeross the four stages, then, eould elarify the relative eeonomie and ethieal advantages
and disadvantages o f different strategies to minimize sueh transfers. Sueh a eomparison,
however, is beyond the seope o f this dissertation.
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Stage one interventions are those that prevent medicines that are not going to be used

from arriving at the household in the first place. It encompasses the conditions that lead
to the presence o f pharmaceuticals in household locations following the manufacture,
distribution, prescribing, dispensing, and purchase. To the extent that pharmaceutical
prescribing and purchase leads to pharmaceutical accumulation in the home, steps can be
taken to reduce the ultimate quantities o f drugs that go unused and accumulate in the
home and then require disposal. These steps include alternative methods o f managing
disease, effective and efficient prescribing practices, and reductions in incentives for
excessive purchasing. Many o f these considerations fall under the “pollution prevention”
concept discussed in detail in Chapter 3 and Ruhoy and Daughton (2008).
The strategy to manage stage two, which is the minimization o f pharmaceuticals that
will not be used, is to improve patient compliance and adherence with prescribed
treatment regimens. Improved compliance may ultimately result in reduced quantities of
drugs that go unused. However, it is important in considering this to simultaneously
avoid encouraging patients to take medications that have been purchased but which turn
out not to be useful, necessary, or to cause unintended effects.
Stage three considers strategies for prudent and safe methods o f disposal of
pharmaceuticals that inevitably go unused. This stage encompasses those steps that must
be taken as a society to ensure proper stewardship o f the products that are manufactured
by producers as well as the products that are purchased by consumers. Central to this
stage is to improve patient awareness o f the need to appropriately dispose o f unused
pharmaceuticals, and o f the opportunities for appropriate disposal options. To the extent
that appropriate disposal options are not readily available, stage three will also include
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adding or improving disposal alternatives. Bound et al. (2005) suggest that environmental

awareness and the perception o f risk may have a positive impact on the motivation of the
consumer to follow prudent disposal recommendations.
Stage four involves means o f lessening the impact o f environmental and human fate
o f pharmaceutical residues, such as treatment technologies. It includes technologies to
remove pharmaceuticals from water or landfills, law enforcement efforts to prevent
pharming or resale o f medicines, clinical treatment or remediation for harm caused, or
financial compensation for harms.
Significantly, the use o f the four stages is an organizing heuristic: in reality, there is
not always a clear differentiation among the stages. Further, interventions at one stage
might have ripple effects on other stages. For example, charging pharmaceutical
companies a penalty if their products are found in the environment is a fourth stage
intervention. However, expecting such penalties might lead those companies to take
preemptive actions most under their control. They might develop new distribution
practices (a first stage intervention), or develop take-back strategies (a second stage
intervention). Thus, while the discussion here is couched in terms of the four stages, it
will be important that these not become reified in future research or in policy applications
o f this research.
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Stage

General Case
(Morgan 1981)
1 Modify the natural
or human
environment

2

Avoid or modify
exposure process

3 Avoid or modify
effects process

Specific Case

Modify likelihood that
households will acquire
pharmaceuticals that will
not eventually be used
Modify likelihood that
acquired pharmaceuticals
will be used

Modify likelihood of
successful transfer of
unused pharmaceuticals
to an appropriate location

Example

Develop alternative
treatments
Change distribution
practices
Minimize non-compliance,
and non-adherence
Promote appropriate
consumption o f prescribed
pharmaceuticals
Facilitate transfer o f unused
pharmaceuticals to
appropriate endpoints
Recognize major routes of
inappropriate transfer
Develop take-back
programs

4

Mitigate or
compensate for
effects

Modify likelihood that
pharmaceuticals
transferred to an
inappropriate location
will have an adverse
impact

Educate patients on
appropriate disposal
options
Mitigate impacts of unused
pharmaceuticals that have
been transferred to an
inappropriate location OR
compensate for those
impacts.
Develop sewage treatment
systems that remove
pharmaceuticals

Charge fees to patients,
pharmaceutical companies
or others for inappropriate
transfers
Table 5: Strategies to Abate the Risk o f Transfer o f Pharmaceuticals from Households to
Inappropriate Locations
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As an example, fluoxetine is a commonly prescribed selective serotonin reuptake
inhibitor (SSRI) that has been detected in surface waters (Kolpin et ah, 2002). It is used
to treat patients with clinical and sub-clinical depression. Non-compliance for
antidepressant therapy is particularly high, both because o f the effect on mood and
motivation o f the disease and because o f the nature o f chronic medication use. Keene et
al. (2005) estimated 54% o f patients become noncompliant during SSRI therapy. Indeed,
in the Clark County (Nevada) Coroner data alone, approximately 67,250 mg o f fluoxetine
were identified in the homes o f the decedents for the 13-month study period.
Fluoxetine has been shown to cause growth impairment in frogs (Holmes, 2003),
behavioural alterations in invertebrates (DeLange et al., 2006), and have the potential for
toxicity to other aquatic organisms (Johnson et al., 2007). Fluoxetine is almost
completely removed from wastewater influents with advanced technologies such as
ozonation (Snyder et al., 2006), but may be less effectively removed during treatment
with less advanced and older technologies, such as membrane bioreactor systems (Snyder
et al., 2005).
Risk management strategies as outlined by the four stages and with regards to the
example o f fluoxetine, might consist of: (1) directing patient to alternative treatment
plans for the depression, such as behavioral modification therapy, homeopathic and
naturopathic remedies, or lifestyle changes, particularly patients with minor and not
major depression; (2) increased management and follow-up o f patient to assess and
improve upon adherence to medication treatment plan; (3) educating patients on safe
methods of disposal, whether these be guidelines by federal organizations, state-specific
waste handling regulations, or locally available take-back programs or returns; and (4)
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improved technology regarding the removal and transformation o f fluoxetine and its

metabolites in water as well as increased resources dedicated to study the effects o f the
unintended human exposure to fluoxetine in the environment.
First Stage
The first stage is the arrival (or not) at a household o f pharmaceuticals that, for one
reason or another, will not be used as intended (table 5, row 2). Stage one is where one
can modify the likelihood that households will acquire pharmaceuticals that will not
eventually be used. Management strategies minimize acquisition o f pharmaceuticals that
will not be used at households, The distinction between appropriate and inappropriate
locations for pharmaceuticals must begin with the acknowledgment o f the appropriate use
and transfer o f pharmaceuticals. Pharmaceuticals designed for human use save lives and
ameliorate symptoms so as to provide millions o f people with an improved quality of life.
They improve health outcome and many o f these medications have prevented untold
levels of human epidemics and demise. A relatively recent class o f pharmaceuticals and
one with expanding sales includes those designed for elective usage by the consumer for
lifestyle purposes, such as cosmetic and aesthetic use. Elective usage implies not
primarily directed by a physician but by the patient. This may lead to prescriptions that
would otherwise not have been written.
Pharmaceuticals that are optimally and appropriately prescribed to patients are
dispensed and ultimately arrive at appropriate locations, such as the consumer household.
Chapter 3 (see also Ruhoy and Daughton, 2008) explored various methods physicians
and pharmacists may use to help minimize wasted pharmaceuticals and therefore by
extension the inappropriate transfer o f medication to inappropriate locations. These
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recommendations would serve to improve health outcomes and health care resource
management as well. As the field o f medicine progresses, physicians may be better able
to tailor treatment regimens for genetic variants o f individual patients.
Genetic medicine is quickly becoming an important emerging discipline in clinical
medicine. The practice o f pharmacogenetics utilizes individual genetic information to
improve the efficacy o f the treatment selected. “Rational drug design” (Yildirim et al.,
2007) would take into account individual and disease-specific protein targets for better
treatment response. Tests to determine genetic variations and genetic profile are
becoming increasingly popular and requested (Katsanis et al., 2008). As this practice
improves and increases, the optimal treatment may be prescribed for a patient and this
may not only improve compliance, but also will most likely minimize the quantity of
medications prescribed and dispensed during the course o f treatment.
Optimal prescribing patterns are complex to assess and even more difficult to
implement. Optimal prescribing patterns would take into account not only the most
effective medication in terms o f biochemical and biophysical effects on the disease
course o f the patient, but also takes into consideration the behavioral patterns o f that
individual patient. The decision on what to prescribe can be based on many factors. For
example, the consistence presence o f drug samples influenced physicians to prescribe
drugs that differed from their “preferred” drug choice (Chew et al., 2000).
Non-compliance with treatment regimens can have significant public health
i

implications. It is not part of standard training for a physician to assess the probability of
compliance by that patient and in any case, the information is not readily available.
Literature on compliance studies indicates it would depend not only on the medication
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and the disease being treated, but personality characteristics and socioeconomic factors of
that patient (Ellis, 2000). Yet decreased accumulation o f pharmaceuticals in appropriate
locations would require an understanding o f the probability o f proper compliance by an
individual patient. Otherwise, even the most effective and efficiently prescribed
medication would ultimately go unused.
Regardless, it is important for physicians and other prescribing health care
professionals to minimizing the transfer, or the arrival, o f pharmaceuticals most likely to
go unused to appropriate locations. Focusing on the household, there are many options
for the reduction o f this transfer, such as unit dosing, trial scripts, and reduction in the use
of samples.
Second Stage
The second stage is the success or failure o f patients to use prescribed
pharmaceuticals as intended (table 5, row 3). Stage two is where one can modify
likelihood that acquired pharmaceuticals will be used. Management strategies promote
appropriate consumption o f prescribed pharmaceuticals. Factors that reduce or increase
the amounts o f unused pharmaceuticals that accumulate and are therefore at risk o f
inappropriate transfer are varied. Most reasons focus on directed or undirected behaviors
by consumers. Compliance with prescribed medication regimens is a problem most
physicians face in their practice. There are many reasons why patients discontinue
treatment. Some o f these reasons are valid, such as intolerable effects or a change in
severity/course o f the disease process, and may even be physician directed, such as
change in treatment plan due to adverse events or ineffectiveness.
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However, often a patient will cease taking prescribed medication either partially or
completely. The potential for non-compliance depends upon not only individual, and life
choices they are confronted with, but also with the medication itself. Some medications
require complicated consumption directions, either with frequency, timing, dosing, or co
consumption with other products, such as food or drug products. Other medications
require knowledge o f difficult delivery systems, such as inhalers or syringes. Finally,
some medications result in expected, but adverse effects, which will likely lead to poor
motivation on the part o f the patient to consume the medication. Regardless, noncompliance and non-adherence will lead to accumulated drugs.
Compliance rates in the literature can range anywhere from 0% to 100%, depending
on the patient, the disease under treatment or the treatment itself. Studies have identified
particular personality traits that may have a higher incidence o f non-compliance (Cohen
et al., 2004). These traits are not always obvious during a typical physician visit and
therefore may go unnoticed and unattended by the prescribing physician. Patients may
also not recognize the severity o f their disease and the importance o f their medication to
prevent and forestall further progression and morbidity.
Some disease processes themselves can present difficulties for the patient to follow
treatment plans. Fatigue, myalgias, neuralgias, paralysis, and depression can all result
from disease and may leave the patient unmotivated, or incapable, to access medication.
It is not without surprise that there is a high non-compliance rate with anti-depressant
medications.
Cessation o f treatment can also result from physician-directed alterations in the
treatment plan. Side effects, adverse effects, or intolerable effects o f medication are often
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valid reasons for exchanging the current plan for a new one, with the resultant leftover
medication. Treatment can also be halted because the desired effects are not appreciable
and the disease course requires intervention.
Third Stage
The third stage is the failure or success o f consumers to transfer unused
pharmaceuticals to appropriate locations (table 5, row 4). Stage three is where one can
modify likelihood o f successful transfer o f unused pharmaceuticals to an appropriate
location. Management strategies facilitate transfer o f unused pharmaceuticals to
appropriate endpoints. A range o f technical, legal and informational constraints limit the
available strategies at this stage. The term “appropriate” thus includes several
dimensions, including whether the location is secure in the sense o f minimizing release to
humans and / or the environment, as well as whether it is legal to make the transfer.
Likewise, consumers may have no or limited knowledge about which transfer endpoints
are appropriate and which are inappropriate.
Locating, identifying, and quantifying accumulated unwanted pharmaceuticals in all
locations beyond the household medicine cabinet and healthcare facilities would serve to
prevent the eventual routine need for disposal o f these expired and otherwise unusable
drugs into the environment. A centralized system o f inventorying and monitoring all
systems and locations where pharmaceutical compounds are dispensed and distributed
could ensure their proper collection and disposal.
Secure locations would ensure public and environmental safety. These sites would
prevent both humans and pets from inadvertently or intentionally accessing unused drugs.
Law enforcement organizations would be the ideal location for unwanted medication
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storage. These sites are protected from the public, and at the same time staffed with
personnel charged with protecting the public. Currently, police officers are permitted to
confiscate pharmaceuticals that are seized during the act o f apprehending criminals and
during criminal investigations. Extension o f this standard to include all areas o f law
enforcement, such as state and federal Drug Enforcement Administration personnel, to
accept unwanted pharmaceuticals from their respective communities would offer sites for
medication drop-off.
Since the CSA prohibits the possession o f controlled substances by anyone other than
the end-user, it is difficult to devise a strategy for a centralized storage o f unused drugs
since it is not feasible to consider only medications that are not controlled. Consumers
often are not familiar with the medications they are prescribed much less whether they
are considered controlled substances. Therefore, law enforcement would serve to protect
the public from diversion by housing those substances most vulnerable to acts o f crime
and abuse. At the same time, environmental safety would be preserved, as pharmaceutical
waste residues would be prevented from entering natural systems.
Collection events at locations such as pharmacies and government edifices are a good
alternative for at least the collection o f these drugs, if not final storage. The issues once
again surround the enforcement o f the CSA. If collection events can have law
enforcement involvement, they may able to circumvent the problem o f accepting
controlled substances. O f note, the US EPA Office o f Child Health and Protection has
i

issued a grant to the University o f Maine for a mail-back pilot prograhii Consumers are
given envelopes with their prescriptions in which they return unused medications. These
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drugs are mailed to the Maine DEA who collects and stores the medications for later
disposal by incineration after transport by reverse distributors.
While awareness is increasing thanks to many programs as well as media interest,
consumers are still unsure o f what to do with their unused pharmaceuticals. Certainly,
some local areas are more active and have held well-publicized take-back events. Yet
nationally the public remains contused. There does not exist a consensus o f a
standardized solution or a generally accepted method o f disposal. Further research to
decide safe and prudent methods o f disposal is warranted.
Fourth Stage
The fourth and final stage is the mitigation o f and/or compensation for impacts of
pharmaceuticals that have been inappropriately transferred (table 5, row 5). Stage four is
where one can modify the likelihood that pharmaceuticals transferred to an inappropriate
location will have an adverse impact. Management strategies mitigate impacts o f unused
pharmaceuticals so transferred or compensate for those impacts. Wide ranges of
strategies are effective here. For example, most pharmaceutical manufacturers have
stewardship standards and practices for their products. With some overlap o f a stage three
intervention, Pfizer maintains a Global Environment, Health, and Safety Policy that
ensures contribution to “protect the natural and workplace environment by advising
purchasers and users.. .about the safe handling and disposal o f our products (Pfizer,
2007)” . Bristol-Meyers Squibb acknowledges recent reports o f the detection of
pharmaceutical residues in water systems (Bristol-Myers Squibb, 2008) and states the
company’s support o f further research. Merck has issued a public policy statement
(Merck, 2007) promising continued collaboration with stakeholders to promote and
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support research in understanding the environment impacts o f pharmaceutical products.
Indeed, working through the Pharmaceutical Research and Manufacturers o f America
(PhRMA), Merck and other pharmaceutical manufacturers, together with the US Fish and
Wildlife Service and the American Pharmacists Association, support the “SMARxT
DISPOSAL” program (US FWS, 2007) which strives to educate the public about proper
use and handling o f medications. An additional relevant note is the recent announeement
by PhRMA o f new guidelines regarding the interactions between healtheare professionals
and pharmaeeutical manufaeturer representatives (PhRMA, 2008). These new guidelines
are intended to remove the pereeption o f influence on the prescription choices o f the
healthcare practitioner, an important overlapping factor for stage one interventions.
Resources should be directed for researeh and development o f reducing the
environmental impacts of existing pharmaceuticals without compromising their
therapeutie effieacy, or identifying alternate eompounds with equal therapeutie effieaey
but less environmental impact. For example, Sanderson et al. (2004a) found modifying
additives to be most toxie in risk assessment o f approximately 4,500 compounds, which
included several pharmaceutical classes and their adjuvants. They recommended redueed
use o f these additives as a way o f potential pollution prevention.
The Food and Drug Administration (FDA) requires the preparation o f an
environmental risk assessments (US FDA, 1998) for most pharmaceuticals proposed for
human use. However, eurrent assessments only require short-term tests that measure how
much o f a compound is required to kill an organism outright or stunt its growth in a
matter o f days. Longer studies may prove more useful. Furthermore, preparation o f this
environmental assessment ordinarily is required unless the proposed action qualifies for a
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categorical exclusion (US FDA, 2008). A categorical exclusion from an environmental

assessment is applied for newly formulated substances that would neither increase the use
o f the active compound, increase the estimated concentration o f the compound in the
aquatic environment, nor would it change the distribution o f the active compound, its
metabolites, or its degradates in the environment. The rate o f new molecular entities
released into the market has decreased over the past decade (AP, 2007). Generic switches
and new formulations o f pre-existing APIs dominate new drug approvals. Therefore, it
may be fair to conclude that fewer environmental assessments are being required for new
drug approvals in recent years.
Crucial to understanding the likelihoods and consequences o f potential impacts of
inappropriately transferred pharmaceuticals is identification and quantification of
ultimate accumulation hotspots (landfills, sewage treatment systems). Chapter 3 and
Ruhoy and Daughton (2008) outlined many locations where unused medication may be
found. However, here is no ready source o f data that addresses the quantity and frequency
with which these drugs are inappropriately transferred to these and other locations,
without which proper disposal procedures cannot effectively be enforced.
Pharmaceutical compounds that do enter the environment eventually are presented for
treatment at STPs. Advanced sewage treatments, such as ozonation, can effectively
remove many, if not most, pharmaceutical compounds. However, not all STPs in the US
have updated technology. Sewage treatment systems are resource intensive. They require
a substantial investment of land, labor, and funds. Problematically, some compounds are
refractory to even the most advanced technology. For example, Snyder et al. (2006)
demonstrated greater than 90% removal o f target compounds using ozonation. However,
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meprobomate, an anxiolytic drug, and iopromide, tri-iodinated x-ray contrast agent,

continued to be recalcitrant. Ying et al. (2007) found estrone and 17a-ethinylestradiol,
both synthetic estrogens, to be persistent during different treatment technologies. Other
studies by Snyder et al. (2007) demonstrate presence of several refractory compounds
following different treatments, such as activated carbon and membrane bioreactors, but
clearly display the efficiency o f a multi-tiered treatment approach in the reduction of
concentrations o f pharmaceutical residues. Resources should be directed for research to
upgrade and improve water treatment systems.
Crucial to effective mitigation/compensation is the understanding o f the likelihoods
and consequences o f impacts from each pharmaceutical agent. An appropriate protocol
evaluates the potential effects of chronic, low-level exposure, as well as some specified
mixture toxicity tests to account for the high probability o f exposure to fnultiple
pharmaceutical residues. Cooper et al. (2008) were able to rank pharmaceuticals in terms
o f risk o f exposure based on physical, chemical, and toxicological data. Cardiovascular,
anti-microbials and central nervous system agents were highly represented.
Once signs and symptoms o f exposure to environmental concentràtions o f
pharmaceutical compounds are identified, first-line treatment will most likely take place
in the office o f a healthcare practitioner. Treatment should be directed at the disease
process assessed on an individual basis. As discussed for stage one intervention,
treatment should be prudently and efficiently chosen. Alternative forms o f treatment for
toxicant exposure should be developed and considered. A recent article by McCoy (2008)
addressed the benefits o f bentonite clay for treatment o f pharmaceutical exposures.
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Finally, inappropriate transfers do not only result in low-dose human or ecosystem
exposures; another problem is the effects o f intentional or unintentional transfer to
persons other than the prescription recipient. Drug diversion and abuse can have
substantial public health consequences (NDIC, 2008). Law enforcement, from the local to
international levels, represents one management strategy. Their role includes preventing
drug diversion and punishing those who commit drug crimes. Another mitigation
measure is treatment o f those who abuse and continue to seek drugs through criminal
means. Strategies to mitigate this exposure include further training o f law enforcement
officials, increased funding o f social welfare programs, and improved addiction services

Conclusion
This chapter has outlined a broad risk management perspective on reducing the
impacts o f transfers o f pharmaceuticals from households to inappropriate endpoints. The
next steps for this approach include both developing the details o f the risk management
stages for households, as well as applying it to the other accumulation locations.
Importantly, any future assessment that applies the four-stage risk management approach
developed above should attend to the whole model in addition to its parts. The four-stage
model is a heuristic, and sticking to it too strictly could obscure important feedbacks
among the stages, and obscure the important dimension o f time.
I have assessed existing conditions, as well as identified critical knowledge gaps, in
the accumulation o f unused pharmaceuticals in society. In addition, I have addressed the
impacts and implications o f various strategies to modify the accumulation environment.
In the final chapter o f this dissertation, I provide some brief conclusions about the ethical.
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resource and policy implications o f changing the accumulation environment and the
approach to prescription drugs.
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CHAPTER 5

CONCLUSIONS AND RECOMMENDATIONS
Academia, the public sector and the private sector increasingly prioritize research into
the potential impacts o f pharmaceutical residues, and effective means o f handling and
discarding unused and unwanted medications. However, current data, ipfbrmation and
models provide limited to guidance for improved management. This dissertation provides
a foundation in terms o f estimating types o f releases, the range o f accumulation locations
in society and mitigation strategies including pollution prevention and a four-stage risk
management approach.
Several areas o f further research are critical to improving management strategies.
First, additional research is needed into fundamental information about sources and
quantities o f accumulation and disposal. Second, considerable progress could be made in
assessing the range o f policy options for changing prescription, distribution and disposal /
return practices.
Research is needed into the human behaviors that motivate physicians to prescribe
medications, and patients to continue or discontinue medications that they have been
prescribed. It will be incumbent upon society to examine these behaviors and motivating
factors. Interaction between doctor and patient will probably require longer times in order
for both parties to gain a better understanding o f the intent and motivation o f the other.
Yet if we are able to use pharmaceuticals in the most efficient manner and not necessarily
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as a primary and reflexive eourse o f treatment, and if we eould provide more information

and more guidance for patients through their treatment course, it is very likely we can
reduce the demand, the supply, and the subsequent accumulation o f unused and unwanted
drugs.
The environment withstands and sustains insult and injury as a consequence to human
ends. Its resilience cannot necessarily be relied upon for generations to come. In the
Tragedy o f the Commons, Garrett Hardin states “it is clear that we will greatly increase
human misery if we do not, during the immediate future, assume that the world available
to the terrestrial human population is finite”. Humans and their activities should be
curtailed so that the ecological resources on which humans rely but often dismiss will
continue to be in an appropriate state o f health to deliver those services. Just as
physicians may counsel patients to make better health and life choices so that the body
may continue to serve them into older age, humans as a species should consider care for
their environment and ecological landscape in order for the ecosystem to maintain
effective balance.
Human activities must be guided by ecological rationality (Roling and Jiggins, 2001).
The proposed recommendations for the curtailment o f pharmaceutical consumption and
behaviors can be appraised using a framework devised by Garry Brewer (1973) as
outlined by Lee (2001). Specifically, the recommendations should be assessed based on
its conceptual soundness, technicality, ethical limitations, and pragmatism.
Finally, there are more questions than answers regarding the presence of, and our
exposure to, pharmaceuticals in the environment. We do know that they are consistently
and continuously prescribed, dispensed, and all too often not consumed as intended. We
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do know these unwanted medications accumulate and find their way to an inappropriate
location, ultimately the natural environment. There is probably danger to aquatic,
amphibian, and terrestrial wildlife and there is potential risk to human health as well.
Human health can be affected by both exposure to environmental contaminants and
diversion, and subsequent misuse, o f prescription drugs.
We don’t yet know to what extent the disposal o f unused medication, as opposed to
excretion, contributes to the pharmaceutical residues detected in water systems.
Undoubtedly, both excretion and direct disposal result in pharmaceutical compounds in
the water. However, consumption and disposal behaviors are more readily modifiable.
Yet in order to justify diverting resources to help improve how we as a society prescribe,
how we as patients consume and adhere, as we as producers become stewards of our
product, and as we as consumers strive towards a more sustainable world through our
actions, behaviors, and perceptions, we must research and collect information with regard
to what drugs are accumulating at inappropriate locations, how often they accumulate,
and how and when they are discarded.
As shown in chapter two, coroner offices are a ready source o f information, but there
are other opportunities for data collection as well, such as at the numerous take-back
events and collection programs currently underway in cities across the nation or at
healthcare institutions. The data will help us understand the drugs that most commonly
remain unused, which will guide physicians, scientists, and policymakers in their efforts
to curb the incidence of unused drugs and the presence o f their residues in waters.
We are only beginning to investigate the role o f prescribed drugs in our society and
the result o f their inappropriate presence. Pharmaceuticals as environmental pollutants
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are regulated, but our limited understanding o f their origins, quantities, fate and transport
leaves us uncertain about how effectively we have done so. Without this assessment,
policies to minimize the exposure cannot be implemented. Once the policies can be
implemented, they must be enforced with constant vigilance.
In addition, pharmaceuticals as primary treatment for patients may have become, in
many instances, more reflexive and reactive than practical. Health care practitioners and
patients alike have been bombarded with advertisement and information about the use o f
medications at a rate much greater than any methodical assessment and consideration can
take place. This has led to greater prescription rates, excessive purchasing, and,
ultimately, greater accumulation and eventual disposal.
The risk o f exposure exists, yet the consequence o f that risk has not yet been
delineated. Pharmaceuticals are designed to be biologically active at low concentrations
and were intended for a specified population (e.g., those suffering from a particular
disease process). Pharmaceuticals were not designed nor intended for consumption by an
unspecified population or for inappropriate accumulation and inappropriate transfer to
inappropriate locations. The risk to life in close proximity to, and therefore directly
dependent on, river and lake water has been partly established but the risk o f life up the
food chain has been underestimated since the exposure o f any particular compound has
been found to be at very low concentrations, particularly in drinking water.
Exposure to therapeutic doses is not the concern. The concern remains that if
inappropriate accumulation and transfer were to continue to occur unabated, the
persistent exposure to low doses o f a multitude o f biologically active compounds over
decades could potentially result in detrimental effects on human health, especially on
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vulnerable populations such as infants and the immunocompromised. Methods o f risk

mitigation and abatement cannot be calculated until the risk o f inappropriate
accumulation and transfer is established.
Many groups and organizations are working diligently on deciding the most prudent
means o f disposal o f unwanted medications. Methods o f destruction are being
investigated (i.e., Abburi et al., 2007; Snyder et al., 2006; Snyder et al., 2007), pilot
collection events are taking place (i.e., IISG, 2007), and there is great discussion on what
to instruct the consumer to do with inappropriately accumulated medication (i.e., US
FWS, 2007). The excess of unused drugs needs to be dealt with, certainly. But the
ultimate objective should remain no leftover drugs.
A complete absence of leftover drugs would require a concentrated effort to
understand human behaviors and human genetics. A recent focus on hedlth, nutrition, and
lifestyle advocate the incorporation of organic, whole foods, and supplementation to help
prevent disease. Personalized medicine would allow for the most effective medication
prescribed, but also the most efficient dose. This would be in contrast to the generic and
mass prescribing for all having a certain physical complaint, as dictated by the many
medicinal algorithms currently used by health care practitioners.
Personalized medicine, sometimes referred to as medical genetics or
pharmacogenetics, strives to identify within each individual the genetic makeup that may
or may not make them not only susceptible to disease, as done with screening tests, but
I

also to better predict the response to treatment. With a customized treatment strategy, a
patient may be more apt to understand what the treatment is for and what improvements
in their current health status they can expect. This would almost certainly improve
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compliance. Enhanced prescribing patterns and superior consumption behaviors would
lead to improve health outcomes and a healthier environment.
Environmentally safe and yet accessible and affordable methods o f disposal for
pharmaceutical ingredients is a generally accepted ideal, as is the idea that we need to
protect public health. Less general but still compelling is the need to change our drugcentric healthcare system, and to understand more holistically the relationship between
human health and the environment. Our ecosystem is subject to unexpected and
sometimes surprising change because o f unrecognized vulnerabilities. To evolve into a
sustainable society we must closely examine our actions and our behaviors to evaluate
the short- and long-term effects. We all play roles in our places in society, whether it is
physician, policymaker, scientist, educator, consumer, or manufacturer. Each role has a
responsibility and those responsibilities are not mutually exclusive. The final outcome
will depend upon the intent of each role player and the extent to which each role is filled.
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